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Abstract 
 
The histone deacetylase inhibitors (HDACis) are a class of chemically heterogeneous 
anticancer agents of which suberoylanilide hydroxamic acid (SAHA) is a prototypical 
member. SAHA derivatives may be obtained by the three-dimensional manipulation of the 
SAHA aryl cap, such as the incorporation of a ferrocene unit like that present in Jay Amin 
hydroxamic acid (JAHA) and homo-JAHA (Spencer et al., 2011). These metal-based SAHA 
analogues have been tested for their cytotoxic activity toward triple-negative MDA-MB231 
breast cancer cells. The results obtained indicate that of the two compounds tested, only 
JAHA was prominently active on breast cancer cells with an IC50 of 8.45 μM at 72 h of 
treatment. For this reason JAHA only was used for the subsequent experiment at 8.45 μM 
concentration. Biological assays showed that exposure of MDA-MB231 cells to the HDACi 
resulted in cell cycle perturbation with an alteration of S phase entry and a delay at G2/M 
transition and in an early production of reactive oxygen species followed by mitochondrial 
membrane potential (MMP) dissipation and autophagy inhibition. No annexin binding was 
observed after short-(5 h) and longer (24 and 48 h) term incubation with JAHA, thereby 
excluding the promotion of apoptosis by the HDACi (Librizzi et al., 2012). An in 
vitro “scratch assay” has also been performed to measure migration of cells treated with 
JAHA for 24 h, but preliminary indications suggested that JAHA had no effect on the motile 
behaviour of MDA-MB231 cells. Subsequently, in order to identify protein signatures 
associated to its cytotoxic activity, we utilized a proteomic approach to reveal protein 
expression changes after 18, 24 and 48 h of exposure. Protein identification was performed 
by mass spectrometry, and a total of eleven differentially-expressed proteins were visualized. 
In parallel, Differential Display (DD) gene expression analysis was used to identify gene 
signatures in the MDA-MB231 human breast cancer cell line after exposure to JAHA. The 
result obtained by DD-PCR were confirmed by Real Time PCR analysis. Further study were 
required to compare the reported signature pattern with that obtained after exposure of 
MDA-MB231 cells with the parental molecule SAHA, and to understand the biological 
implications of the expression changes found. A further set of assays was designed to check 
the effect of JAHA on the intracellular signaling pathways of MDA-MB231 breast cancer 
cells. Concerning the MEK pathway JAHA repressed MAP kinase (ERK) activation after 18 h 
and up to 30 h of treatment, and also down-regulated DNA (cytosine-5-)-methyltransferase 1 
(DNMT1), a downstream ERK target, already at 18 h with an increase up to 48 h of exposure.  
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To check the occurrence of changes in the extent of global DNA methylation, genomic DNA 
was submitted to MeSAP (Methylation Sensitive Restriction Arbitrarily-Primed) PCR (Naselli 
et al., 2014) using Afa and then HpaII enzymes followed by PCR amplification with an 
arbitrary primer binding preferentially to guanine and cytosine (GC)-rich regions of DNA, 
including CpG islands. Preliminary indications suggest the ability of JAHA to induce 
hypomethylation patterns in tumoral breast cancer cells after 30 h of the treatment. 
Collectively, these data demonstrate that the HDACi JAHA, by inhibiting ERK activity, 
regulates DNMT1 expression and ultimately DNA methylation. Although caution must be 
exercised in extrapolation of the vitro results to the in vivo situation for which research on 
animals and human trials are needed, nevertheless JAHA treatment possesses the potential 
for its development as an agent for prevention and/or therapy of “aggressive” breast 
carcinoma, thus prompting us to get more insight into the molecular basis of its anti-breast 
cancer activity. 
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1. Introduction 
 
1.1 Breast cancer 
 
Breast cancer is the most common cancer diagnosed in women globally. More than 1 million 
women are affected by the disease each year and it is estimated that 400.000 women will die 
due to breast cancer (Laurentiis et al., 2010). Cancer is generally characterized by 
uncontrolled cell division, cell transformation, and escape of apoptosis, invasion, 
angiogenesis and metastasis. One of the challenges of treating breast cancer is the 
heterogeneity between various tumors (Polyak, 2011). Breast cancer can be classified in 
multiple ways. Traditionally, classification was histological, separating breast cancers into 
ductal, lobular, nipple, or not otherwise specified. However, molecular classification using 
immunohistochemistry to reflect the hormone-responsiveness of the tumors and other cell 
markers has become increasingly useful for dictating treatment and prognosis. The molecular 
subtypes of breast cancer, which are based on the presence or absence of estrogen receptors 
(ER), progesterone receptors (PR), and human epidermal growth factor receptor-2 (HER2), 
include: luminal A (ER+ and/or PR+; HER2–), luminal B (ER+ and/or PR+; HER2+), basal-
like (ER–, PR–, and HER2–), and HER2-enriched (ER–, PR–, and HER2+) (Hsiao et al., 
2010; Viale, 2012), (figure 1.1). 
 
Figure 1.1. Molecular subtypes of breast cancer – hormone receptor and growth factor status. ER – Estrogen 
Receptor, PR – Progesterone Receptor, ERBB2/HER2 – Human Epidermal growth factor Receptor 2 
(http://www.labmed.ascpjournals.org). 
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It is important to note that not all tumors in a specific histological subtype belong to the same 
molecular classification. Additionally, the hormone responsiveness does not determine the 
molecular subtype. For example, not all tumors with HER2+ receptors are of the HER2-
enriched mRNA subtype, and not all tumors in the HER2-enriched mRNA subtype are 
clinically HER2 receptor-positive. In addition a variety of genetic and epigenetic changes has 
been implicated in the development of breast cancer, in particular somatic gene mutations, 
copy number aberrations, exon sequencing changes, alterations in miRNA and protein 
expression levels, and changes in methylation and acetylation levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Triple-negative breast cancer 
 
Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, 
approximately 170.000 will harbour the triple-negative phenotype (Anders et al., 2009). 
Triple-negative breast cancer (TNBC) does not express the ER, PR or the HER2 receptor 
hence the triple-negative status. Although most basal like cancers do not express ER, PR and 
HER2 receptors some do, therefore the small overlap between basal like and TNBC is 
generally insensitive to the standard targeted drugs for breast cancer as many current therapies 
tend to target the receptors, for example, Herceptin and anti-oestrogen therapies (Zordoky et 
al., 2014). Since TNBC does not have any of the receptors, it is much more difficult to treat 
and there is often a poor prognosis. Therefore, the testing of new or pre-existing novel drugs 
in the treatment of triple-negative breast cancer is paramount. 
 
1.3 Epigenetic control of gene expression 
 
In eukaryotes DNA is packaged into chromatin fibers to achieve compaction, enabling the 
entire genome to fit into the nucleus, and allowing DNA transcription, replication, and repair, 
when necessary (figure 1.2). 
The nucleosome is the basic repeating unit of chromatin polymer and consists of 146 bp of 
DNA wrapped around a histone octamer (Marks et al., 2001). Histones are small basic 
proteins conserved throughout evolution and consist of a globular domain flanked by a 
carboxy-terminal and a lysine rich amino-terminal tail composed of positively charged 
residues. The core histone octamer is formed by two copies of each of histones H2A, H2B, 
H3 and H4 organized in an H3-H4 tetramer and two H2A-H2B dimers.  
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The binding of Histone H1 to linker DNA sequences between nucleosomes leads to a further  
chromatin compaction, by mechanisms that remain poorly defined (figure 1.3). 
 
 
 
 
Figure 1.2. Organization of DNA into chromatin, nucleosome fibers are packaged into higher order structures 
giving rise to chromosomes (http://www.bouzoki.files.wordpress.com). 
 
 
 
 
Figure 1.3. Schematic representation of a nucleosome. DNA is wrapped around core histone octamer which 
contains two H3-H4 tetramers centrally located and two flanking H2A-H2B dimers. Histone H1 links 
nucleosomes into higher order structures (http://www.mun.ca). 
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Histone lysine tails protruding from the nucleosome are sites of post-translational 
modifications including acetylation, methylation and ubiquitination of lysine (K) residues, 
phosphorylation of serine (S) and threonine (T) residues, methylation of arginine (R) and 
ADP ribosylation of glutamic acid residues (Zhang et al., 2001), (figure 1.4). 
 
 
 
 
Figure 1.4. Histone modifications include acetylation (ac), methylation (me), phosphorylation (ph) and 
ubiquitination (ub1). Most of the known histone modifications occur on the N-terminal tails of histones, with 
some exceptions including ubiquitination of the C-terminal tails of H2A and H2B and acetylation and 
methylation of the globular domain of H3 at K56 and K79, respectively. Globular domains of each core histone 
are represented as coloured ovals (http://www.nature.com). 
 
Strahl (2000) proposed that distinct histone modifications, on one or more tails, act 
sequentially or in combination to form a 'histone code' that is read by other proteins leading to 
distinct downstream events. This theory states that posttranslational modifications can act 
through two mechanisms that are not mutually exclusive: (i) by structurally changing the 
chromatin fiber through internucleosomal contacts thus regulating the access of transcription 
factors to the DNA; and (ii) by generating docking sites for effector molecules that, in turn, 
initiate distinct biological processes. The histone code is part of the epigenetic information 
found into the cells. The term “epigenetics” refers to mitotically and meiotically heritable 
changes in gene expression that are not coded in the DNA sequence itself (Egger et al., 2004). 
Indeed, DNA methylation is another well studied epigenetic mechanism. Methylation at the 
C-5 position of cytosine residues present in CpG dinucleotides by DNA methyltransferases 
(DNMTs) is generally considered to facilitate static long-term gene silencing (Lund et al., 
2004). 
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1.4 DNA Methylation 
DNA methylation and histone modifications are two principal factors in epigenetic 
phenomena. These two mechanisms perform a crucial function in carcinogenesis and tumor 
progression. DNA methylation is controlled by DNA methyltransferase (DNMT), an enzyme 
that catalyzes the transfer of a methyl moiety from S-adenosyl-l-methionine to the 5-position 
of cytosines in the CpG dinucleotide (Robertson, 2001). DNMT overexpression has been 
detected in a variety of malignancies, including lung, prostate, and colorectal tumors (Eads et 
al., 1999; Lin et al., 2007; Manoharan et al., 2007). Because DNA methylation is a reversible 
biochemical process, DNMT may be a viable target for the treatment of cancer. Since two 
cytidine analogues, 5-azacytidine and 5-aza-2'deoxycytidine, have been reported in the 1980s, 
several DNMT inhibitors are currently under investigation for their possible utility in treating 
a variety of tumors (Schneider et al., 2007; Mai et al., 2009). It has become widely accepted 
that histone modification and DNA methylation are intricately interrelated in terms of 
affecting chromatin structure and gene expression (Hashimshony et al., 2003). Because these 
two parameters have long been implicated in the regulation of cellular response, histone 
deacetylase (HDAC) inhibitors and DNMT inhibitors might be considered potential targets 
for the cancer.  
 
1.5 Histone acetylation 
 
 
To date, acetylation is the most extensively studied histone posttranslational modification and 
involves the transferring of an acetyl group from the metabolic intermediary acetyl coenzyme  
to the ε-amino group of a lysine residue. The primary effect produced by acetylation is the 
partial neutralization of the positive charge of the histones, thus decreasing their affinity for 
the DNA, altering nucleosome-nucleosome interactions and enabling chromatin 
decondensation to allow transcriptional activation (Jenuwein et al., 2001; Vaquero et al., 
2003). Although it is known that the four core histones (H2A, H2B, H3, and H4) can be 
acetylated in their N-terminal tails, the H3 and H4 modifications are mainly responsible for 
the effect on transcription. The balance between acetylated and deacetylated states of 
chromatin is regulated by histone acetyltransferase (HAT) and histone deacetylase (HDAC) 
enzymes (Marks et al., 2001; Minucci et al., 2006). HATs transfer acetyl groups to amino-
terminal lysine residues in histones, which results in local expansion of chromatin and 
increased accessibility of transcription factors to DNA, whereas HDACs catalyse the removal 
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of acetyl groups, leading to chromatin condensation and transcriptional repression (figure 
1.5). 
 
 
 
 
 
Figure 1.5. Schematic representation of the equilibrium between HDAC and HAT activities  (Johnstone, 2002). 
 
1.6 Histone deacetylases  
 
1.6.1. Classification and localization 
 
 
 
 
The HDACs can be divided into two families (table 1.1), (Tauton et al., 1996) the Zn
+2
 
dependent HDAC family composed of class I (HDACs 1, 2, 3 and 8), class II a/b (HDACs 4, 
5, 6, 7, 9 and 10), and class IV (HDAC 11) and (Glaser et al., 2002) Zn
+2
-independent NAD-
dependent class III SIRT enzymes.  
 
 
 
 
 
 
 
Table 1.1. Classification of HDAC family. 
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Based on their homologies to yeast HDACs, mammalian HDACs can be divided into four 
classes (table 1.2) (Glaser, 2007). Class I comprises HDAC1, 2, 3 and 8, which are related to 
the yeast HDAC rpd3, and these HDACs are located in the nuclei of the cells. Class IIa/b 
HDACs, homologous to yeast hda1, have both histones and non-histone proteins as 
substrates, are primarily localized to the cytoplasm but they can shuttle to nucleus through 
association with 14-3-3 proteins. Specifically, HDAC 4, 5, 7 and 9 fall into Class IIa, whereas 
Class IIb contains the HDAC6 and 10, which have two catalytic sites (Dokmanovic et al., 
2005). It was reported that HDAC11 has a conserved domain in the catalytic region of both 
Class I and Class II enzymes (Fischle et al., 2002) and it has been grouped to Class IV 
HDAC. Zn
+2
-independent and NAD-dependent Class III HDACs are homologues to yeast 
sir2, and they are virtually unaffected by the HDAC inhibitors that are now in clinical trials. 
At present, the applications of HDAC inhibitors in therapy of cancer or other diseases are 
mainly pointed to Zn
+2
-independent Class I and II HDACs. 
 
 
 
 
 
Table 1.2. The classification of HDACs in mammals (Lucio-Eterovic et al., 2008). 
 
The class II enzymes are characterized by either a large N-terminal domain or a second 
catalytic domain (HDAC 6 which contains both a histone and a tubulin deacetylase catalytic 
domain). The class III SIRTs are NAD
+
 dependent deacetylases with non-histone proteins as 
substrates (in mammalian cells) and have been linked to regulation of calorific utilization of 
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cells (only in yeast the SIR proteins are known to be histone deacetylases) (Bolden et al., 
2006). HDACs do not function independently but rather in concert with multi-protein 
complexes (e.g., NCoR, SMRT, MEF, MeCP2, Sin3A, etc.), (Ng et al., 2000) that are 
recruited to specific regions of the genome that in turn generate the unique spectrum of 
expressed and silenced genes that are characteristic of the expression profiles responsible for 
the malignant phenotype of cancer cells. 
 
1.6.2 Mechanism of action 
 
 
 
The mechanism of action of the HDAC enzymes involves removing the acetyl group from the 
histones comprising the nucleosome. Hypoacetylation results in a decrease in space between 
the nucleosome and the DNA which is wrapped around it. Tighter wrapping of the DNA 
diminishes accessibility for transcription factors, leading to transcriptional repression (figure 
1.6), (Strahl et al., 2000; Wade, 2001). 
 
 
Figure. 1.6. HAT and HDAC mechanism of actions (http://www.hindawi.com). 
 
The catalytic domain of HDAC is formed by a stretch of ~390 amino acids consisting of a set 
of conserved amino acids. The active site consists of a gently curved tubular pocket with a 
wider bottom (Finnin et al., 1999). Removal of an acetyl group occurs via a charge-relay 
system consisting of two adjacent histidine residues, two aspartic residues (located approx. 30 
amino acids from the histidines and separated by approx. 6 amino acids), and one tyrosine 
residue (located approx. 123 amino acids downstream from the aspartic residues) (Buggy et 
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al., 2000). An essential component of the charge-relay system is the presence of a Zn
+2
 ion. 
This atom is bound to the zinc binding site on the bottom of the pocket. However, other 
cofactors are required for HDAC activity since most recombinantly expressed enzymes are 
found to be inactive. HDACi function by displacing the zinc ion and thereby rendering the 
charge-relay system dysfunctional. TSA, with its hydroxamic acid group and its five-carbon 
atom linker to the phenyl group, has the optimal conformation to fit into the active site 
(Finnin et al., 1999). There have been indications that histone hypoacetylation frequently 
occurs in tumor cells, and the disorder of histone acetylation level is associated with 
carcinogenesis (Mahlknecht et al., 2000). Abnormal transcriptional silencing of certain 
cancer-related genes mediated by overexpression of HDACs that are recruited by transcription 
factors may be a cause of carcinogenesis. 
 
1.6.3 Structure of the HDACs 
 
 
 
The structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a 
homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% 
identity with human HDAC1 over 375 residues, deacetylates histones in vitro. It consists of a 
central eight-stranded parallel -sheet and sixteen -helices as shown in figure 1.7. 
 
Figure 1.7. HDLP structure (Finnin et al., 1999). 
 
Four helices pack on either face of the -sheet, forming the core  structure characteristic of 
this class of folds. Most of the remaining eight helices are clustered near one side of the -
sheet. Large, well-defined loops originate from the carboxy-terminal ends of the -strands 
(loops L1-L7; figure 1.7). The extra helices and the large L1-L7 loops are associated with a 
significant extension of the structure beyond the core  motif. This gives rise to two 
Chapter 1: Introduction 
 
22 
 
prominent architectural features: a deep, narrow pocket and an internal cavity adjacent to the 
pocket (figure 1.8).  
 
Figure 1.8. Space-filling representation of TSA in the active-site pocket (Finnin et al., 1999). 
 
The pocket has a tube-like shape with a depth of ~11 Ǻ. The pocket opening constricts 
halfway down to ~4.5 by 5.5 Ǻ, but becomes wider at the bottom. The pocket and its 
immediate surroundings are made up of seven loops. These originate from strands near the 
centre of the sheet (L3-L7) and from the additional helices that pack near the ends of the 
strands. The walls of the pocket are covered with hydrophobic and aromatic residues that are 
identical in HDAC1 (Pro22, Gly140, Phe141, Phe198, Leu256 e Tyr296). Of particular 
significance are Phe 141 and Phe 198, whose phenyl groups face each other in parallel at a 
distance of 7.5 Ǻ, marking the most slender portion of the pocket. In the crystal structure of 
the zinc-reconstituted enzyme, the zinc ion is positioned near the bottom of the pocket, just 
beyond its narrowest point. It is coordinated by Asp 168, His 170, Asp 258 and a water 
molecule. The protein ligands are arranged in a tetrahedral geometry, but the position of the 
water molecule, which also hydrogen-bonds to His 131, deviates from this geometry by ~25°. 
In addition to the zinc ligands, the bottom of the pocket contains two histidines (His 131 and 
His 132), two aspartic acids (Asp 166 and Asp 173) and a tyrosine (Tyr 297), all of which are 
identical in HDAC1. The Asp 166-His 131 charge-relay pair is positioned deeper inside the 
pocket, and is more buried than the Asp 173-His 132 charge relay, which is partially solvent 
exposed. The internal cavity is made up of portions of the L3 and L7 loops as they emerge 
from the -strands and the 1-L1-2 segment. The L1 loop, which demarcates the cavity 
from the solvent, has higher temperature factors than the rest of the structure, indicating some 
inherent exibility that may allow the transient exchange of the cavity contents with the bulk 
solvent. The cavity is lined primarily with hydrophobic residues and is particularly rich in 
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glycine residues. There are only two charged residues in the cavity and these are contributed 
by the L1 loop (Arg 27 and His 21). The function of the cavity is not clear. It is possible that 
it provides space for the diffusion of the acetate product away from the catalytic centre, which 
may otherwise be crowded and shielded from the solvent when the substrate is bound. The 
HDLP-HDAC1 homology maps mainly to the hydrophobic core and to the L1-L7 loops, with 
the portions of the loops that make up the pocket and adjacent cavity having the highest level 
of conservation. Specifically, all of the polar residues in the active site and the hydrophobic 
residues that make up the walls of the pocket are identical. Among the residues that make up 
the internal cavity, the ones closest to the active site are either identical or conservatively 
substituted. The HDLP active-site residues that are identical in HDAC1 are also conserved in 
the class II histone deacetylases. One exception is Asp 173 of the exposed charge-relay 
system, which is an asparagine in some class II HDACs. The 375-amino-acid HDLP protein 
corresponds to the histone deacetylase catalytic core that is conserved across the HDAC 
family. The one region likely to have a less similar structure is the 40-residue C terminus of 
HDLP (335-375), which has significantly lower homology to HDAC1 (Finnin et al., 1999).   
 
1.7 Histone deacetylase inhibitors 
 
 
 
 
Natural and synthetic inhibitors of HDAC have not only contributed to the discovery of 
HDAC enzyme molecules and the elucidation of their functions but have also developed as 
attractive therapeutic agents for diseases including cancer. After the disclosure of the crystal 
structure of the HDAC-like protein bound to the inhibitor, the momentum of research on 
HDAC inhibitors increased, and several inhibitors are currently under clinical trials. One of 
the most important developments in this field of research was the isolation of specific HDAC 
inhibitors from natural sources. In the early 1990s, trichostatin A (TSA) and other fungal 
antibiotics such as trapoxin (TPX) were shown to inhibit HDAC at nanomolar concentrations 
and to allow the induction of histone hyperacetylation in living cells (Yoshida et al., 1995; 
Kijima et al., 1993). In addition, it is becoming increasingly clear that reversible acetylation 
of proteins other than histones is one of the key post-translational modifications controlling 
the activity of proteins. The HDACi have been widely used as powerful tools for 
identification and functional analysis of the acetylated non-histone proteins. The clinical 
importance of the HDAC inhibitors has been emphasized, in particular for cancer treatment. 
These agents act selectively in altering the transcription of relatively few of the expressed 
genes (generally 2% to 10% of expressed genes are increased or decreased in their rate of 
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transcription), (Van Lint et al., 1996; Butler et al., 2002). The first compound described as an 
inhibitor of HDAC activity was sodium butyrate (Candido  et al., 1978). 
The effect of butyrate as a noncompetitive inhibitor was shown with a partially purified 
enzyme (Cousens et al., 1979). However, its effective concentration exceeds millimolar 
levels, which raised the possibility that it affects other enzymes, the cytoskeleton and 
membranes. Therefore, butyrate should be used with caution. TPX, which had been 
discovered to induce morphological reversion of transformed phenotype to normal in several 
oncogene transformed cells, was also shown to inhibit HDAC (Kijima et al., 1993). In 
contrast to TSA, TPX was an irreversible inhibitor of HDAC. Cocrystallization of the 
bacterial histone deacetylase-like protein (HDLP) with TSA demonstrated that TSA mimics 
the substrate and that TSA binds by inserting its long aliphatic chain into the tube-like HDLP 
pocket and inhibits the enzyme activity by interacting with the zinc and active-site residues 
through its hydroxamic acid at one end of the aliphatic chain (Finnin et al., 1999). 
Hydroxamic acid, a functional group of the inhibitor, coordinates the zinc through its 
carbonyl and hydroxyl groups, resulting in the formation of a penta-coordinated zinc. The 
classes of compounds that have been identified as strong HDAC inhibitors have basic 
structures mimicking that of TSA, which possesses an aromatic group as a cap, an aliphatic 
chain for a spacer, and a hydroxamic acid as a functional group interacting with the active-site 
zinc. The functional groups include carboxylates, hydroxamic acids, electrophilic ketones 
containing epoxyketones, anilides, and thiols (figure 1.9).  
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Figure 1.9. Basic structure of the HDACi (TSA) (http://www.en.wikipedia.org/wiki/Trichostatin_A). 
 
Several structurally distinct classes of HDC inhibitors have been developed, including 
hydroxamic acid, cyclic peptides, electrophilic ketones, short-chain fatty acids, and 
benzamides (Drummond et al., 2005; Beckers et al., 2007), (table 1.3). 
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Table 1.3. HDAC inhibitors in clinical trials as anticancer agents (Lee et al., 2007). 
 
 
 
 
 
 
1.8 Short-chain fatty acids 
 
 
 
This class of compounds is characterized by a short plasma half-life, non-specificity and low 
power due to the short aliphatic chain which limits the contact with the catalytic pocket of 
HDACs. Some require high concentrations of the order of millimolar, to exert their inhibitory 
action; are therefore not suitable for clinical use. Sodium butyrate causes cell cycle arrest in 
G2/M and cell death by apoptosis; it promotes the acetylation of histones and maturation of 
granulocytes in acute myeloid leukemia and, in humans, selectively inhibits the growth of 
tumor cells in the prostate and carcinoma of the cervix. Sodium valproate inhibits HDAC at 
millimolar concentrations; has been shown to reduce the growth of endometrial cells in 
humans and, in acute myeloid leukemia, reduces cell proliferation and induces apoptosis 
(Miller et al., 2003; Yoshida et al., 2003; Marks et al., 2007).  
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1.9 Hydroxamic acids  
 
 
This class of inhibitors is very similar for both HDAC class I and class II; they contain the 
function hydroxamic acid that binds with high affinity to the catalytic residue by HDAC and 
prevents the substrate access to the zinc ion. The general structure of these molecules consists 
of a hydrophobic linker that allows the hydroxamic group of chelating the cation on the 
bottom of the pocket while the rest of the molecule blocks access to the pocket itself. Most of 
the molecules belonging to this group show a high power, acting on micro and nanomolar 
doses in vitro, but are reversible inhibitors of Class I and II HDAC. Trichostatin (TSA) was 
one of the first HDAC inhibitors identified and is often used as a reference (Yoshida et al., 
2003). It was developed as an antifungal but is relatively unstable; its toxicity and its lack of 
specificity, however, have led to the search for other molecules. As mentioned previously, the 
design of many inhibitors, however, was inspired by its structure. The TSA blocks the 
proliferation and triggers apoptosis in hepatocellular carcinoma cells, blocks the cell cycle in 
Hela cells and ovaries cancer cells. Simple hydroxamic acids such as SAHA have shown 
activity in submicromolar doses. SAHA is a second generation polar-planar compound that 
induces cell growth arrest, differentiation and/or apoptosis and it is under clinical trial for the 
treatment of  haematological and non-haematological tumors. 
 
1.10 Epoxides 
 
 
These molecules may act by chemically modification in the nucleophile active site with the 
epoxy group and forming hydrogen bonds with the ketone; they are likely to block the HDAC 
through the reaction of the epoxy molecule with zinc or with an amino acid of the active site, 
forming a covalent bond. The high reactivity of the epoxy group drastically reduces the 
bioavailability of these molecules and makes them of little interest from the pharmacological 
point of view. The only inhibitors belonging to this class are a series of natural compounds 
with an in vitro significant activity as the trapoxina (TPX) A and B (Miller et al., 2003; Marks 
et al., 2007). 
 
1.11 Cyclic Peptides  
 
 
 
Cyclic peptides such apidicin, have a molecule of ethylketone, and the depsipeptide inhibit 
HDAC at nanomolar doses (Miller et al., 2003).  
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It seems that the apidicin interacts with the catalytic site and inhibits cell proliferation in 
several cancers. The depsipeptide is a natural product derived from Chromobacterium 
violaceum and shows potent antitumor activity with a mechanism still not well known.  
 
1.12 Benzamides  
 
 
 
The mechanism of action of this group of inhibitors is unknown but it seems that they inhibit 
histone deacetylation and cellular proliferation at the level of the transition between G1 and S 
phases of the cell cycle. MS275 and some of its derivatives inhibit HDACs in vitro at 
micromolar doses; it is assumed that the diaminophenyl group is very important for the 
purposes of its inhibitory activity; probably both amino functions chelate the metal ion in the 
catalytic site. MS275 induces cell cycle arrest in G1 increasing the expression of the cyclin-
dependent kinase inhibitor (CDKI) p21Waf-1/Cip1. MS275 has demonstrated 
antiproliferative activity in several human tumor cell lines (lung, breast, colon, leukemia, 
ovary and pancreas) (Beckers et al., 2007). 
 
 1.13 Hybrid Compounds  
 
 
The compounds are composed of semi-synthetic hybrid (Müller et al., 2012) born from the 
union of cyclic tetrapeptides and hydroxamic acid groups of TSA or SAHA; they can 
reversibly inhibit HDAC at nanomolar concentrations and showed selectivity of action for 
HDAC1 and HDAC4. 
 
1.14 HDACi mechanism of action 
 
Activation of differentiation programmes, inhibition of the cell cycle and induction of 
apoptosis are the key antitumor activities of HDACis. These biological effects are due to 
HDACi-dependent alteration in the acetylation level of histones, transcription factors and 
other proteins. In fact, the inhibition of HDACs causes the release of these enzymes from 
transcription factor complexes and the recruitment of HATs which acetylate histones favoring 
decondensation of chromatin structure and activation of transcription of tumor-suppressor 
genes or other genes crucial for the normal functioning of cells (Marks et al., 2001). Although 
histone deacetylation has a fundamental role in regulating gene expression, HDAC inhibitors 
seem to directly affect transcription of only a relatively small number of genes (2-10%).  
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Different HDAC inhibitors activate a common set of genes indicating that certain loci are 
more susceptible to these compounds than others, in particular those that control cell growth 
and survival (Johnstone, 2002). Moreover, HDAC substrates include also non-histone 
proteins such as transcription factors (e.g. p53, E2F), signal transduction mediators (e.g. 
STAT3), DNA repair enzymes (e.g. Ku70), chaperone proteins (e.g. Hsp90), structural 
proteins (α-Tubulin), steroid receptors (ERα). HDACis induce an increase in acetylation level 
of these proteins affecting their function, stability or protein-protein interaction (Xu et al., 
2005; Spange et al., 2009).  
In fact, p53 acetylation increases its stability and binding to DNA leading to transcriptional 
activation of different p53 target genes including pro-apoptotic genes (e.g. Bax) (Minucci et 
al., 2006). Moreover, acetylation in the DNA-binding domains of Ku70 reduces its ability to 
repair drug-induced DNA damage, thereby sensitizing cancer cells to agents producing DNA 
double-strand break as radiations. This effect may account for the increase of tumor cell 
sensitivity to chemotherapy and radiotherapy following HDACi treatment (Minucci et al., 
2006). One of the main effects of HDACis is inhibition of the cell cycle which is a necessary 
event in cellular differentiation. Almost all HDACis activate transcription of the cyclin-
dependent kinase (CDK) inhibitor p21/WAF1 encoded by the CDKN1A gene inducing 
acetylation of histones at the level of this locus. However, the induction of p15/INK4b 
(CDKN2B), p16/INK4a (CDKN2A) and p27/Kip1 (CDKN1B) CDK inhibitors at 
transcriptional level has also been reported (Marks et al., 2001). The increase in the level of 
p21/WAF1 or other CDK inhibitors causes hypophosphorylation of retinoblastoma tumor-
suppressor protein RB and arrest of cell cycle in G1 phase (Johnstone, 2002). Analysis of the 
cell-cycle profiles of tumor cells treated with HDAC inhibitors indicates that the cells often 
arrest in G1, but sometimes accumulate in the G2 phase of cell cycle. In fact, it has been 
demonstrated that SAHA at low concentration predominantly induces G1 arrest, while high 
concentration induces both G1 and G2/M arrests in bladder carcinoma cell lines (Richon et al., 
2000). Furthermore, SAHA has been also reported to inhibit the growth of pancreatic cancer 
cells and non-small cell lung cancer cells (NSCLC) in a dose-dependent manner inducing 
G2/M cell cycle arrest, apoptosis and differentiation. Most tumor cells that do not arrest in G1, 
after HDACi treatment, replicate their DNA and subsequently arrest in G2 checkpoint 
(Johnstone, 2002), (figure 1.10). 
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Figure 1.10. Multiple HDACi-activated antitumor pathways. HDACi can induce transformed cell growth arrest, 
terminal differentiation, cell death and/or inhibition of angiogenesis. The cell death pathways identified in 
mediating HDACi-induced transformed cell death include apoptosis via the intrinsic and extrinsic pathways, 
mitotic catastrophe/cell death, autophagic cell death, senescence and reactive oxygen species (ROS)-facilitated 
cell death (http://www.discoverymedicine.com). 
 
However, many tumor cell lines accumulating replicated DNA and hyperacetylated histones 
undergo apoptosis (Johnstone, 2002). In this context, HDACis can induce cell death of tumor 
cells activating both mitochondrial (intrinsic) and death-receptor (extrinsic) pathways of 
apoptosis. The pathway activated depends on the cell type and class of HDAC inhibitor used. 
The intrinsic apoptosis pathway is usually triggered in response to stress conditions such as 
cytotoxic drugs, UV irradiation, and requires disruption of the mitochondrial membrane by 
Bcl-2 family pro-apoptotic members Bax and Bak. Following a death stimulus, the cytosolic 
monomeric Bax translocates to the mitochondria where it becomes an integral membrane 
protein and oligomerizes giving rise to voltage dependent anion channels which lead to 
mitochondrial outer membrane  permeabilization (Johnstone et al., 2007). This event induces 
the release from the mitochondria of cytochrome c and other pro-apoptotic factors, such as 
Smac/DIABLO (Second Mitochondria-derived Activator of Caspases). Cytochrome c binds 
and activates Apaf-1 which in turn activates caspase-9 starting caspase cascade (Johnstone, 
2002).  
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Smac/DIABLO binds and antagonizes the caspase inhibitors IAPs (inhibitors of apoptosis). 
Caspases are cysteine aspartate proteases expressed as inactive zymogens (pro-caspase) and 
proteolitically processed to an active state after an apoptotic stimulus. Initiator caspases (e.g. 
caspase-2, -8, -9 and -10) cleave inactive pro-forms of effector caspases, thereby activating 
them. Effector caspases (e.g. caspase-3, -6 and -7), in turn, cleave other protein substrates 
within the cell, to trigger the apoptotic process. Bcl-2 family also includes pro-apoptotic Bad 
and Bim, and antiapoptotic Bcl2 and BclxL proteins. Bad and Bim stimulate activation of the 
intrinsic pathway preventing the antiapoptotic function of Bcl2 and BclxL. HDACis can alter 
the balance of expression of pro- and anti-apoptotic genes to induce a pro-apoptotic response. 
Indeed, SAHA causes upregulation of proapoptotic (Bax and Bim) and downregulation of 
antiapoptotic (IAP, Bcl-2, Bcl-xL) genes. Different HDACis induce also the cleavage of the 
pro-apoptotic protein Bid resulting in a C-terminal fragment (tBid) which translocates to 
mitochondria and induces the oligomerization of Bax and Bak opening the mitochondrial 
voltage-dependent anion channel (Johnstone et al., 2003). The extrinsic pathway of apoptosis 
is mediated by death receptors including Fas (Apo-1 or CD95), tumor necrosis factor (TNF) 
receptor-1 (TNFR-1), TNF-related apoptosis-inducing ligand (TRAIL or Apo2-L) receptors 
(DR-4 and DR-5). All death receptors are characterized by a cysteine-rich extracellular 
domain and an intracellular cytoplasmic sequence motif known as the death domain (DD). 
The binding of Fas-Ligand (Fas-L), TNFα and TRAIL ligands induce trimerization of their 
receptors and clustering of the receptor DD leading to the recruitment of the adaptor protein 
FADD (FASAssociated Death Domain-containing protein or MORT1) which interacts with 
the death domain of the receptors through its own death domain. FADD also contains a death 
effector domain (DED) near its amino terminus, which facilitates binding to the DED of 
procaspase-8 and its activation. This complex (receptor-FADD-procaspase-8) of interacting 
proteins is referred to as the death inducing signalling complex (DISC) (Johnstone  et al., 
2007). Procaspase-8 is activated by autoproteolytic processing and the resulting active 
caspase-8 cleaves and activates downstream effector caspases such as caspase-3, -6, and -7. 
Caspase-8 can also proteolitically activate Bid which can start the mitochondrial pathway 
amplifying the apoptotic signaling. HDACis can upregulate the expression of both death 
receptor and their ligands in transformed cells but not in normal cells (Xu et al., 2005). 
Indeed, it has been reported that Fas and FasL are induced in human neuroblastoma cells by 
hydroxamates, in nude mice xenograft of human osteosarcoma cells by FK228 and mouse 
model of acute promyelocytic leukaemia by valproic acid. TRAIL is induced at mRNA level 
in acute myeloid leukaemia cells by SAHA and MS-275 and both TRAIL and DR5 are 
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induced in the mouse model of APL by valproic acid. TNFα is upregulated by FK228 in 
human promyelocytic leukemia cells (Xu et al., 2005). Therefore, extrinsic apoptotic pathway 
can account for HDACi-induced cell death in many transformed cells. 
 
1.15 HDACi and cell cycle inhibition  
 
 
As reported previously, the inhibition of HDAC results in the increase of the acetylation 
levels of histone proteins and other  proteins causing a series of events that differ between 
them according to the spectrum of selectivity of the inhibitor towards the various HDAC 
based on the cellular context of the tumor. In most cases the antitumor activity is based on the 
ability to activate programs of differentiation, inhibit the progression of the cell cycle and 
induce apoptosis. It also seems to be very important the ability to activate the immune 
response and inhibition of angiogenesis. The acetylation of p53 is increased during cellular 
stress (Luo et al., 2000), stopping the repression by Mdm-2 (Tang et al., 2008; Palani et al., 
2010), increasing the affinity for the DNA (Harms et al., 2007), reducing the ubiquitin-
mediated degradation of the transcription factor and increasing the expression of p21 WAF1/ 
Cip1 (Zhao et al., 2006). A number of studies have demonstrated the activation of p53 after 
the inhibition of HDAC (Zhao et al., 2006; Condorelli et al., 2008). However, some work 
reported that apoptosis and induction of p21 determined by the inhibition of HDACs can be 
induced in a p53 independent manner, a remark that this may be clinically relevant for the 
tumors treatment with p53 mutated (Gui et al., 1999, Saito et al., 1999; Sowa et al., 1999; 
Peart et al., 2003; Lindemann et al., 2004). The histones hyperacetylation leads the relaxation 
of chromatin structure and facilitates the expression of several regulatory genes. Treatment 
with HDAC inhibitors, in fact, causes an increase in the expression of the cyclin-dependent 
kinase inhibitor p21 WAF1, the repression of genes encoding for cyclins A and D, and the 
inhibition of thymidylate synthetase, which is involved in DNA synthesis. These events are 
likely to contribute to the arrest of the cell cycle phases G1/S, in particular they increase the 
levels of p21 WAF1 tumor suppressor, which binds and inhibits the activity of CDK, induce 
hypophosphorylation of pRb, p107 and p130 proteins, the suppression of cell proliferation 
and cell-cycle arrest in G1 phase. In normal cells, the HDACi activate a cell cycle control at 
the G2 phase that is missing in many cancer cells; the loss of this control causes aberrant 
mitoses in cancer cells that lead to death. This block in G2 phase by treatment with HDACi 
could be the basis of selective action on tumor cells (Dokmanovic et al., 2005; Drummond et 
al., 2005). 
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1.16 HDACi and apoptosis  
 
 
 
As already discussed, apoptosis, also known as programmed cell death, is a genetically 
regulated process of fundamental importance for tissue homeostasis and development. 
Apoptosis is morphologically characterized by the formation of protuberances ("blebs") in the 
cytoplasmic membrane, cell shrinkage, chromatin condensation, exposure of 
phosphatidylserine, DNA degradation and cell fractionation in smaller vesicles that are 
internalized by phagocytic cells (Meech et al., 2001; Cory et al., 2002). Apoptosis is achieved 
through the activation of cysteine proteases known as caspases (Thornberry et al., 1998), 
mediated by two "pathway" (extrinsic) mediated by receptor and the mitochondrial pathway 
(intrinsic) (Johnstone, 2002). The apoptosis pathways are finely regulated at different levels 
and the dysregulation may be the cause of human diseases including cancer (Rossi et al., 
2003; Vermeulen et al., 2005). The correlation between the proper function of HDAC and cell 
survival has been widely demonstrated; it is known, in fact, as the inactivation of HDAC6 
interfere with cell survival by triggering an apoptotic mechanism of cell death (Hideshima et 
al., 2005). HDAC inhibitors induce apoptosis probably through the activation of different 
mechanisms. The treatment with these molecules seems primarily able to alter the expression 
of genes involved in the proapoptotic response; it is in fact increased the transcription of 
genes such as TRAIL, Fas and Bak and decreased the transcription of genes such as XIAP and 
bcl-2. In addition the HDAC inhibitors would also be able to induce apoptosis through the 
increased production of oxygen radicals. High levels of TBP2 (thioredoxin-binding protein 2), 
generally low in cancer cells can be the cause of apoptosis. SAHA, HDAC inhibitor, 
selectively increases the expression of TBP2, which binds and inactivates reduced 
thioredoxin. This protein is important for the redox reactions of the cell, the action of SAHA 
increases the sensitivity of the cell to oxidative stress and can cause apoptosis.  
 
 
 
 
1.17 HDACi and autophagy  
 
 
 
Autophagy, is a process preserved through evolution in which the proteins and cellular 
organelles are sequestered in autophagosomes and finally degraded after fusion with 
lysosomes. 
Three forms of autophagy have been described: macroautophagy, microautophagy and 
chaperone-mediated autophagy (figure 1.11) which differ in their physiological functions and 
transport mode (Reggiori et al., 2002; Wang et al., 2003).  
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Figure 1.11. Three forms of autophagy: macroautophagy, microautophagy and chaperone-mediated autophagy 
(http://www.autophagy.lu). 
 
 
 
 
 
The double cell membrane invaginates, melts, forming a vesicle, called autophagosome, 
which fuses with the lysosome, an acid organelle, forming the autolysosome (figure 1.12). 
The lysosomal acid hydrolases degrade the components in their elementary forms (free 
nucleotides, fatty acids, amino acids) that can be used to recover ATP and other molecules 
critical for the biosynthetic pathway in hypoxia or nutrient depletion conditions. (Noda et al., 
1998; Levine et al., 2004; Carew et al., 2010).  
 
 
      Figure 1.12. Schematic diagram of the cellular events during autophagy (http://www.wormbook.org). 
 
 
 
 
Autophagy involves a complex "pathway" of cellular events characterized by different 
proteins. One of the key proteins in the autophagy regulation is TOR kinase that inhibits the 
autophagic process in the presence of growth factors and abundant nutrients (Noda et al., 
1998). Although p53 can positively regulate autophagy through a stress induced protein 
known as DRAM (Damage-Regulated Autophagy Modulator); a p53 target gene (Crighton et 
al., 2006).  
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TOR regulates more than 30 genes called "autophagy-related" which encode for proteins 
essential for the autophagy (Klionsky et al., 2003), including beclin 1 and LC3, which is used 
in the laboratory to monitor the autophagy process. This protein can be in two forms: LC3-I 
and LC3-II. The form LC3-I is predominant in normal cell and diffuse into the cell; when 
autophagy is induced, LC3-I is cleaved in the form LC3-II (Tanida et al., 2004 a and 2004 b) 
and inserted in the membrane of the autophagosome (Kabeya et al. 2000). It was shown as 
HDACs are required for autophagy, in particularly for the fusion of lysosomes with 
autophagosomes (Iwata et al., 2005). The role of autophagy in cancer and its potential interest 
as a therapeutic target are still controversial. There are experimental evidences that support 
the theory that autophagy acts as a tumor suppressor gene and therefore could be stimulated to 
reduce the occurrence of breast cancer (Liang et al., 1999, Qu et al., 2003; Karantza et al., 
2007; Mathew et al., 2007). However, there are other experimental evidence showing as the 
survivor effects induced by autophagy may actually help the cancer cells to proliferate, 
especially in stressful conditions such as high proliferative rate, the hypoxic conditions in 
solid tumors and the lack of nutrients in the metastatic conditions (Paglin et al., 2001; Abedin 
et al., 2007; Apel et al., 2008; Qadir et al., 2008; Samaddar et al., 2008). 
 
1.18 Effects of HDAC on cell motility and angiogenesis  
 
Cell motility plays a crucial role in tumor metastasis. The studies on this matter reveal that 
overexpression of HDAC6 increases the motility. (Hubbert et al., 2002). Another aspect 
related to tumor development is the angiogenesis. In tumors the formation of new blood 
vessels can be realized from a preexisting vascular thanks to the recruitment of circulating 
cells such as endothelial progenitor cells derived from bone marrow, macrophages and 
fibroblasts (Adams et al., 2007; Kerbel, 2008). These cells together with the malignant 
cytotypes are capable to secret proangiogenic factors including vascular endothelial growth 
factor (VEGF) produced by induction of the transcription factor hypoxia inducible factor 1 
alpha (HIF-1alpha), which induces the formation of new blood vessels (Kim et al., 2001). It 
was shown that the hypoxic conditions regulate the function of HDACs both directly and 
indirectly (Kim et al., 2001; Mahon et al., 2001). Specifically it has been shown that hypoxic 
conditions in different cell lines in vitro, increase the expression of mRNA for HDAC1, 
HDAC2 and HDAC3 and other proteins (Kim et al., 2001). In addition, overexpression of 
HDAC1 average the reduced expression of p53 and pVHL that induces the overexpression of 
HIF-1 α and its target transcriptional VEGF, that situation is reversed when using the histone 
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deacetylase inhibitor trichostatin A (TSA) both in vitro and in vivo (Kim et al., 2001). The 
condition by which the reduction in the expression of p53 and pVHL in turn helps to reduce 
the expression of the inhibitory factor HIF-1 α, thus allowing the induction of angiogenesis in 
endothelial cells has also been described (Mahon et al., 2001). These results clearly 
demonstrate that the HDACs indirectly regulate the activity of HIF-1 α in hypoxic conditions. 
But the HDACs also act directly on HIF-1 α to regulate its activity. It has been shown, for 
example, that HDAC1 and HDAC3 directly regulate the stability and transcriptional activity 
of HIF-1 α through the interaction with the oxygen-dependent degradation domain (ODDD) 
of HIF-1 α (Kim et al., 2007). These studies demonstrate that the HDACs play a critical role 
in angiogenesis induced by hypoxia and they represents a new strategy in cancer therapy 
through they ability to inhibit angiogenesis itself. At present there are numerous preclinical 
and clinical studies that confirm an anti-angiogenic role of HDACi in the treatment of 
multiple cancers. 
 
1.19 Therapeutic uses of HDACis 
 
 
HDACis mediate a number of molecular changes within cancer cells. These changes in gene 
expression or protein activity and stability can lead to cells that arrest during the cell cycle, 
apoptose or differentiate. Recent research has also shown that the HDACis can decrease 
angiogenesis in some tumors by inhibiting hypoxiainducible factor 1 alpha activity, 
suggesting additional pathways by which the HDACi can be effective at decreasing 
tumorigenesis (Kim et al., 2007; Qian et al., 2006). In cancers that poorly respond to 
chemotherapy, treatment with HDACis can increase the sensitivity of the cancer cells to other 
drugs and treatments such as radiotherapy (Munshi et al., 2005; Hahn et al., 2008). 
Combination of retinoic acid and HDACi therapy has shown promise in cell culture models of 
acute promyelocytic leukemia (APL). In APL, a chromosomal translocation produces the 
fusion protein PML-RARalpha which aberrantly retains deacetylases and the methyl-CpG-
binding protein 1 (MBD1) at the promoters of retinoic acid-responsive genes, thus inhibiting 
normal differentiation of these cells (Fenrick et al., 1998; Villa et al., 2006). Inhibiting HDAC 
activity, or that of DNA methyltransferases, in combination with providing an excess of 
retinoic acid, relieves this repression and allows differentiation to proceed (Fenrick et al., 
1998; Villa et al., 2006). Interestingly, the treatment of cells with HDAC inhibitors also 
indirectly causes proteasomal degradation of the PML-RARalpha fusion protein (Kramer et 
al., 2008). The HDACi currently used in clinical trials inhibit Class I and II zinc-dependent 
HDACs.  
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Little is known about how the HDACis mediate these effects preferentially over non-
cancerous cells. In addition, it is unclear which HDACs are necessary to mediate these 
anticancer effects. The loss of HDAC2 protein was reported in some colon cancer and 
endometrial cell lines and interestingly, this renders the colon cancer cells resistant to TSA 
(Ropero et al., 2006). RNAi experiments that knock-down individual HDACs showed that 
HDACs 1, 3 and 8 were all independently important for cancer cell growth, as knock down of 
any one was sufficient to inhibit growth in specific cancer cell types (Glaser et al., 2003; 
Vannini et al., 2004). These findings suggest that HDAC-specific inhibitors could be effective 
in some cancers, though it is not clear if they would be as effective as the inhibitors that target 
multiple HDACs. The current HDACis which are showing promise in multiple tumor types 
are not without toxic side effects. It will be important to determine which HDACs need to be 
inhibited in specific cancer types in order to obtain the maximum effectiveness of the drugs 
while at the same time minimizing the unwanted toxicity and off-target side effects of these 
drugs. 
Chapter 2 : Aim of the research 
 
37 
 
2. Aim of the research  
 
 
 
The histone deacetylase inhibitors (HDACis) are an emerging class of chemically 
heterogeneous anticancer agents, which restore a relaxed, hyperacetylated, chromatin 
structure potentially leading to re-expression of silenced genes and/or silencing of 
downstream genes, ultimately inducing death, apoptosis, and cell cycle arrest in cancer cells 
also via nonhistone-targeted mechanisms such as perturbations of p53, cytokine signaling 
pathways, and angiogenesis (Dickinson et al., 2010; Kim et al., 2011). HDACis are grouped 
in different categories on the basis of their chemical nature, and the implication of this 
molecular diversity is that the precise mechanism through which these compounds work is 
still poorly understood. Suberoylanilide hydroxamic acid (SAHA), is a prototypical HDACi 
targeting class I and II HDAC approved in 2006 by the Food and Drug Administration for 
treatment of cutaneous T cell lymphoma, (Mann et al., 2007) which has been subjected to 
several manipulations of the core structure to probe the effect of such modifications on both 
HDAC inhibitory activity and cytotoxic effect on cancer cells. Some Authors (Spencer et al., 
2011) have recently reported the synthesis of metal-based SAHA analogues incorporating a 
ferrocene unit, e.g. Jay Amin hydroxamic acid (JAHA) and homo-JAHA. JAHA if compared 
with parental SAHA, displayed similar broad inhibitory profiles toward class I HDACs, 
including HDAC8, although homo-JAHA was less potent toward HDAC6 and more effective 
toward HDAC8, whereas none of them was active on class IIa HDACs. The ability of these 
compounds to restrain the growth of the estrogen receptor-positive, low malignant, MCF-7 
breast tumor cells prompted us to extend the investigation to other neoplastic cell lines, more 
representative of breast cancer histotypes with poor outcome, and also to get more insight into 
the molecular mechanism of the cytotoxic induction. Triple-negative breast cancers lack 
expression of estrogen and progesterone receptors and are human epidermal growth factor 
receptor 2 (HER2)/neu negative, thereby being poorly responsive to hormonal therapies and 
to HER2-targeting drugs and usually associated with worse prognosis than other breast tumor 
types (Kassam et al., 2009). For these reason the present work was aimed to evaluate the 
possibility of an innovative therapy for triple-negative breast cancer based on HDACis, 
investigating the effects and mechanisms of action of novel metal-based SAHA analogues on 
an in vitro model system of triple-negative human breast cancer, i.e. MDA-MB231 cells. The 
realization of this project was made possible thanks to the collaboration with Dr. John 
Spencer of the School of Science, University of Sussex, UK, who provided us with two 
newly-synthesized derivatives of SAHA, i.e. JAHA and homo-JAHA (figure 2.1). JAHA (N
1
-
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(ferrocenyl)-N
8
-hydroxyoctanediamide) is an organometallic analogue of SAHA containing a 
ferrocene group consisting of two cyclopentadienyl rings bound on opposite sides of a central 
metal atom. The incorporation of protein ligands in organometallic parts provides the 
possibility of a better integration in space and ensures a better affinity that could not be 
obtained with rather simple planar aromatic groups or alicyclic rings (Meggers, 2009). 
 
A)
B)
C)
 
 
 
Figure 2.1. Chemical structures of the compounds which have been examined in this study. (A) Suberoylanilide 
hydroxamic acid (SAHA),C14H20N2O3, molecular weight 264.3202. (B) JAHA, C18H24FeN2O3, molecular weight 
372.2398. (C) Homo-JAHA, C19H26FeN2O3, molecular weight 396.35. JAHA and Homo-JAHA were provided by 
courtesy of Dr. John Spencer, University of Sussex, UK ( Spencer et al., 2011). 
 
JAHA is able to bind the enzyme in a similar manner to SAHA, using the interactions 
between the hydroxyamate and the zinc of the catalytic site, with a hydrogen bond between 
the amide portion of the ligand and the Asp 10. The ferrocenyl group of JAHA easily fits into 
the pocket defined by the amino acids Tyr100, Phe152, and Tyr306 (figure 2.2); this region of 
the enzyme is considered malleable and able to adapt the structures of different ligands. The 
homologous homo-JAHA was synthesized to evaluate the effect of the introduction of a 
methylene group as a spacer in JAHA (Spencer et al., 2011). 
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Figure 2.2. Model of JAHA binding to HDAC8 (a) and comparison between JAHA and SAHA (b) (Spencer et 
al., 2011). The zinc ion is colored in cyan. The residues in the binding pocket are represented according to the 
models "ball and stick". In blue the nitrogen, oxygen in red, carbon in grey; JAHA is represented in green and 
SAHA in orange. 
 
Because so far little is known about the biological role of these compounds in experimental 
models "in vitro", the purpose of this research is therefore to estimate the effects related to the 
use of homo-JAHA and JAHA at different concentrations and at different times on MDA-
MB231 cells, considering first the survival dose-dependent time, calculating the IC50 by MTT 
and performing biological and molecular assay to evaluate the cytotoxic effect of this 
compounds on MDA-MB231 breast cancer cells. 
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3. Materials and Methods 
3.1 Materials 
 
 
3.1.1 Chemicals 
 
Acetic Acid         Carlo Erba Reagenti, Rodano, Italy 
Acrilamide solution      Sigma-Aldrich, Steinheim, Germany 
Acrylamide-bisacrylamide (29:1 ratio)   FISHER Molec. Biology, Trevose, USA                                                                                 
Agarose                                                                      Sigma-Aldrich, Steinheim, Germany 
AgNO3       Sigma-Aldrich, Steinheim, Germany 
APS        Sigma-Aldrich, Steinheim, Germany 
β-mercaptoethanol     Invitrogen, Paisley,UK 
Boric acid       Carlo Erba Reagenti, Rodano, Italy 
Bromophenol blue     Sigma-Aldrich, St. Louis, USA 
Butylated hydroxytoluene    Sigma-Aldrich, St. Louis, USA 
Chloroform       Sigma-Aldrich, St. Louis, USA 
Coomassie Blue       Sigma-Aldrich, St. Louis, USA 
DEPC treated water     Invitrogen, Paisley,UK 
DMSO        Sigma-Aldrich, St. Louis, USA 
DNA Loading Dye 6X    Invitrogen, Paisley,UK 
DTT       Thermo Scientific, Waltham, MA, USA 
EDTA        Santa Cruz, Heidelberg, Germany 
 
EGTA       Santa Cruz, Heidelberg, Germany 
Ethanol 96%        Carlo Erba Reagenti, Rodano, Italy 
Ethanol absolute       Carlo Erba Reagenti, Rodano, Italy 
Ethidium bromide     Sigma-Aldrich, St. Louis, USA 
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Formaldehyde 37%      Promega, Madison, USA 
Formic acid      Thermo Scientific, Waltham, MA, USA 
Glycerol      Sigma-Aldrich, St. Louis, USA 
Glycine       Invitrogen, Paisley,UK 
HCl           Carlo Erba Reagenti, Rodano, Italy 
Hydroxyurea      Sigma-Aldrich, St. Louis, USA 
Iodoacetamide      Appli Chem, St. Louis, Missouri, USA 
IPG Buffer      GE Healthcare Life Sciences, Milan, Italy 
Isopropanol                           Sigma-Aldrich, St. Louis, USA 
LiCl       Invitrogen, Paisley, UK  
Methanol                                                                    Sigma-Aldrich, St. Louis, USA 
NaCl        Sigma-Aldrich, St. Louis, USA 
Na2CO3        Riede-de Haen Gmbh,Seelze, Germany 
N, N-methylene bis-acrilamide solution                   Sigma-Aldrich, St. Louis, USA 
Non-fat dry milk     Euroclone, Milan, Italy 
PMSF        Sigma-Aldrich, St. Louis, USA 
SDS        Sigma-Aldrich, St. Louis, USA 
Silanization solution      Fluka Chemie AG, Buchs, Switzerland 
Sodium thiosulfate      Sigma-Aldrich, St. Louis, USA 
TEMED       Sigma-Aldrich, St. Louis, USA 
Terminator™ 5′-Phosphate-Dep. Exonuclease Epicentre, Madison, USA 
Trichloroacetic acid      Sigma-Aldrich, St. Louis, USA 
Trifluoroacetic acid     Sigma-Aldrich, St. Louis, USA 
Triton X-100       Sigma-Aldrich, St. Louis, USA 
Trizma base       Sigma-Aldrich, St. Louis, USA 
Tween 20       Sigma-Aldrich, St. Louis, USA 
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Urea       Invitrogen, Paisley, UK 
λ -Methacryloxypropanyltri-methoxy-silane  Sigma-Aldrich, St. Louis, USA 
 
3.1.2 Consumables 
Afa I       Invitrogen, Carlsbad, CA 
Alkaline phosphatase-conjugated antibody   Promega, Madison, WI 
Amphotericin B      Invitrogen, Carlsbad, CA 
AnnexinV kit  Miltenyi Biotec, Bologna, Italy 
 
Anti-AKT antibody      Cell Signaling Beverly,USA 
 
 
 
Antibiotic/antimycotic     Gibco, Invitrogen, Paisley, UK 
Anti-actin antibody      Sigma-Aldrich, St. Louis, USA 
Anti-Erk1/2 antibody     Abcam, Cambridge, UK 
Anti-DNMT1 antibody     Sigma-Aldrich, St. Louis, USA 
Anti-IgG HRP antibody    GE Healthcare Life Sciences, Milan, Italy 
Anti-LC3 antibody      Sigma-Aldrich, St. Louis, USA 
Anti-p-AKT antibody     Santa Cruz, Heidelberg, Germany 
Anti- p-Erk1/2 antibody     Cell Signaling Beverly, USA 
Anti-p62/SQSTM1 antibody     Sigma-Aldrich, St. Louis, USA 
Bafilomycin A1      Enzo Life Sciences, Lausen, Switzerland 
BCA assay kit       Thermo Scientific, USA 
BCIP/NTB Liquid Substrate System   Invitrogen, Paisley, UK 
Bradford assay      Bio-Rad, Milan, Italy 
BSA         Sigma-Aldrich, St. Louis, USA 
DNA ladder 100 bp      Invitrogen, Paisley, UK 
DNA ladder 50 bp      Invitrogen, Paisley, UK 
dNTPs (100 mM)      Invitrogen, Paisley, UK 
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ExoSAP-IT kit     Affymatrix, Wycombe, UK 
FBS        Gibco, Invitrogen, Paisley, UK 
Fluorescent dye JC1      Invitrogen, Carlsbad, CA  
GelRed       Biotium, Hayward, USA 
HpaII         New England BioLabs, Ipswich, USA 
Montage PCR centrifugal PCR purification filter     Millipore Corporation, Bedford, USA 
Nitrocellulose Membrane      Hybond C, Amersham 
Penicillin/Streptomicin (10 mg ml
-1
)   Invitrogen, Carlsbad, CA   
PBS        Gibco, Invitrogen, Carlsbad, CA 
Power SYBR Green PCR Master Mix   Applied Biosystems Philadelphia, USA 
Propidium iodide      Invitrogen, Carlsbad, CA 
Protease Inhibitor Cocktail     Sigma-Aldrich, St. Louis, USA 
PureLink Genomic DNA kit       Invitrogen, Paisley, UK 
Rapamycin       Santa Cruz Biotechnology, CA 
RPMI        Gibco, Invitrogen, Paisley, UK 
Random primers       Gibco, Invitrogen, Paisley, UK 
REDTaq DNA Polymerase 0,05 U/µl   Sigma-Aldrich, St. Louis, USA 
Ribonuclease H (2U/µl)     Invitrogen, Paisley, UK 
Ribonuclease inhibitor      Invitrogen, Paisley, UK 
RNase A       Invitrogen, Carlsbad, CA 
Stoffel Kit for DD-PCR    Applied Biosystems Philadelphia, USA  
 
 
 
 
 
 
SuperScript II Reverse Transcriptase 200 U/µl   Invitrogen, Paisley, UK 
Taq DNA polymerase recombinant    Invitrogen, Carlsbad, CA 
Thiazolyl Blue Tetrazolium Bromide    Sigma-Aldrich, St. Louis, USA 
Total ROS/ Superoxide Detection Kit    Enzo Life Sciences, Lausen, Switzerland 
Trypsin       Promega, Madison, WI 
Chapter 3 : Materials and Methods 
 
44 
 
Trypsin-EDTA (0,05%)     Gibco, Invitrogen, Paisley, UK 
TRI REAGENT       Sigma-Aldrich, St. Louis, USA 
Western ImmunStar™ C™ Substrate Kit   Bio-Rad, Hercules, USA 
 
3.1.3 Equipment 
Balance               Gibertini Elettronica s.r.l., Novate, Italy 
Burker counting chamber      Fortuna, Germany 
Centrifuge Rotofix 32        Hettich Lab Technology, Tuttlingen 
ChemiDoc  System     Bio-Rad, Hercules, USA 
CO2 incubator       Sanyo Electric, Japan 
FACSCanto apparatus     Biosciences, Franklin Lakes, NJ 
Gel Chamber       Elettrofor, Borsea (Ro), Italy 
Gel electrophoresis power supply      Elettrofor, Borsea (Ro), Italy 
Glass plates Sequi-Gel    BioRad, Hercules, USA 
Heater and magnetic stirrer       ALC International, Milan, Italy 
Laminar flow cabinet, biowizard     Bicasa Spa, Bernareggio, Milan, Italy 
Luminometre Multi Detection System   Promega, Milan, Italy 
     
Nano-Acquity (Waters) LC system    Thermo Electron Corp., San Jose, CA 
and Orbitrap Velos mass spectrometer  
 
Nanodrop spectrophotometer    Thermo Scientific, USA  
 
Novablot equipment      Pharmacia, USA 
 
 
 
pH meter      Crison Instrumentes, Barcelona, Spain 
Phase contrast microscopy      Carl Zeiss, Oberkochen, Germany 
Real Time PCR system 7300    Applied  Biosystems, Almeida, USA g 
Sequencing service      BMR Genomics Padova, Italy 
Sonicator       Sonics & Materials, Newtown, USA 
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Spectrophotometer, DU-730     Beckman Coulter, Milan, Italy 
Thermal Cycler      TECHNE, Bibby Scientific, Milan, Italy 
Thermocycler T1 Plus     Biometria, Gottingen, Germany 
 
TransilluminatorUltra-violet products  Cambrige, UK 
Vortexer, Autovortex     Stuart Scientific, Redhill, UK 
Water bath      Elettrofor, Borsea (Ro), Italy 
 
3.1.4 Buffers and Solutions 
All solution were prepared with ultrapure water: 
 
 
Developing solution                             3% Na2CO3, 200 µl Sodium thiosulfate 
(10 mg/ml), 1.5 ml Formaldehyde 37% 
 
 
 
 
 
Fix stop solution     CH3COOH 10% 
 
 
Lysis buffer                                                 7 M Urea, 2 % CHAMPS, 1% IPG Buffer, 
10 mM DTT, PMSF protease and 
phosphatases inhibitor cocktail 1X  
 
 
 
Running buffer      Tris 0.6%, Glycine 2.88%, SDS 0.1% 
 
 
 
Sample buffer  0.5 M Tris-HCl 12.5%, pH 6.8, 2% SDS, 
10% glycerol, 5% β-mercaptoethanol, 
bromophenol blue 0.05% 
 
Staining solution     0.1% AgNO3, 1.5 ml, Formaldehyde 37% 
 
Stripping buffer  1 M Tris HCl pH 6.8, SDS 10%, β-
mercaptoethanol 50 mM  
 
TBE 10X      89 mM Tris-borate, 2 mM EDTA pH 8.3  
 
 
 
TBS       NaCl 150 mM, Tris-HCl pH 7.4 100 mM 
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TBS-T                           NaCl 150 mM, Tris-HCl pH 7.4 100 mM         
                                                 Tween-20 0.05% 
 
Transfer buffer Tris 0.29%, Glycine 1.44%, Methanol 
20% 
  
3.2 Methods 
 
3.2.1 HDACis 
 
JAHA and Homo-JAHA were synthesized as reported by Spencer et al., (2011) and dissolved 
at 6.5 mM concentration in dimethyl sulfoxide (DMSO) JAHA and Homo-JAHA, and SAHA 
at 3.8 mM as stock solutions. 
 
3.2.2 Cell cultures and viability assay  
 
 
MDA-MB231 breast tumor cells were maintained in RPMI 1640 medium plus 10% fetal 
bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2.5 mg/l amphotericin 
B (Invitrogen, Carlsbad, CA), at 37°C in a 5% CO2 atmosphere. The cells were detached from 
flasks with 0.05% trypsin-EDTA, counted, and plated at the necessary density for treatment 
after achieving 60−80% confluency.  
The assessment of in vitro cytotoxic activity was determined by an 3-(4,5-dimethylthiazol-2-
yl-2,5-diphenyltetrazolium bromide (MTT) assay (http://www.molmeth.org/protocols/ 
1VB7RPF). Briefly, MDA-MB231 cells in exponential growth were plated at a concentration 
of 5500 cells/well in a 96-well plate and allowed to adhere overnight. Then, the cells were 
treated with 0.1, 1, 10, and 100 μM concentration of either drug or with the vehicle (DMSO) 
for 24, 48, and 72 h and observed under the phase-contrast microscope before processing for 
the viability assay. Different amounts of DMSO, equivalent to those diluting the drugs in the 
parallel experiments, were added to cells in the conditions of vehicle-only treatment. Fifteen 
microliters of MTT (final concentration, 0.75 mg/ml) was then added, and after incubation, 
100 μl of SDS-containing solubilization buffer replaced the MTT-containing culture medium 
and dissolved the precipitated violet formazan crystals within metabolically viable cells. 
Absorbance of the dissolved dye was measured in an automated microplate reader at 550 nm. 
The cell viability ratio was determined as the ratio between treated cells and untreated 
controls. IC50 was calculated with Prism 5.0 software (GraphPad, La Jolla, CA). 
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3.2.3 Apoptosis Assay 
 
 
The possible onset of apoptosis was evaluated using the Annexin V-fluorescein 
isothiocyanate (FITC) kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according 
to manufacturer's instructions. Briefly, plated cells were treated with 8.45 μM JAHA for 5, 24, 
and 48 h. Then, attached and floating cells were collected and resuspended in 100 μl of 
binding buffer 1×10
6
 cells, and 10 μl of FITC-annexin V was added. After centrifugation and 
resuspension in 500 μl of binding buffer 1X, propidium iodide was added immediately prior 
to flow cytometric analysis in a FACSCanto apparatus (BD Biosciences, Franklin Lakes, NJ). 
Data were represented as dot plots using Flowing software v.1.6.0., which discriminated 
normal cells (bottom left quadrant) from cells in early apoptosis (bottom right quadrant), cells 
in late apoptosis or early necrosis (top right quadrant), or cells undergoing necrosis (top left 
quadrant). Vehicle-treated cells were tested as parallel controls. 
 
3.2.4 Cell Cycle Analysis 
 
MDA-MB231 cells were seeded in six-well plates at a concentration of 88000 cells/well and 
allowed to adhere overnight and then treated with 8.45 μM JAHA and harvested after 24 and 
48 h of incubation. Cells were resuspended in 0.5% Triton X-100 in phosphate-buffered 
saline containing 0.5 μg/ml RNase A, incubated a 37°C for 30 min, and then treated with 
propidium iodide at 4°C for 30 min in the dark. The cell cycle distribution was analyzed by 
flow cytometry in a FACSCanto apparatus and Weasel 3.0.1 software. Vehicle-treated cells 
were tested as parallel controls. 
 
 
 
3.2.5 Evaluation of ROS Production 
 
The production of ROS, such as hydrogen peroxide, peroxynitrite, hydroxyl radicals, nitric 
oxide, and peroxy radical, and of superoxide was checked using the Total ROS/Superoxide 
Detection Kit (Enzo Life Sciences, Lausen, Switzerland) according to the manufacturer's 
instructions. Briefly, attached and floating MDA-MB231 cells treated with 8.45 μM JAHA 
were harvested after 24 and 48 h of incubation and resuspended in 500 μl of ROS/Superoxide 
Detection Mix and incubated for 30 min at 37°C in the dark prior to flow cytometry assay for 
the green and orange fluorescence in a FACSCanto apparatus. Vehicle-treated cells were 
tested as parallel controls.  
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Positive (pyocyanin-treated) and negative (N-acetyl-L-cysteine-treated) controls were 
included in the analysis, and data were represented as dot plots using Flowing software 
v.1.6.0., which discriminate cells with increased total ROS production (top left quadrant), 
increased superoxide production (bottom right quadrant), and increased total ROS and 
superoxide production (top right quadrant). To assess the involvement of ROS production in 
the cytotoxic effect of JAHA, an MTT assay was performed as already reported on JAHA-
treated cells incubated for 24 h in the presence of the antioxidant butylated hydroxytoluene 
(BHT) at 5, 10, 25, and 50 μM final concentration. 
 
3.2.6 Mitochondrial Membrane Potential (MMP) Assay 
 
 
Control and JAHA-treated cell preparations were stained with the fluorescent dye JC1 
(Invitrogen) according to Cannino et al., (2008) and MMP was then checked by flow 
cytometry, according to Cossarizza and Salvioli, (2001). Essentially, control and JAHA-
treated MDA-MB231 cells, both attached and floating, harvested after 24 and 48 h from 
treatment, were stained with JC1 (final concentration, 2.5 μg/ml) for 10 min at 37°C, washed 
with phosphate-buffered saline (PBS), and analyzed for the green and orange fluorescence in 
a FACSCanto apparatus. Data were represented as dot plots using Flowing software v.1.6.0., 
which discriminate in the bottom quadrants the amount of cells that undergo loss of MMP. 
 
3.2.7 Autophagy Assays 
 
AVOs, which are a hallmark of autophagy, were quantified by flow cytometry as reported by 
Jiang et al., (2009) and Chen et al., (2010). Essentially, control and JAHA-treated MDA-
MB231 cells, both attached and floating, were harvested after 24 and 48 h of incubation and 
stained with acridine orange (final concentration, 100 μg/ml) for 20 min in the dark and then 
analyzed in a FACSCanto flow cytometer. Data were represented as dot plots using Flowing 
software v.1.6.0., which discriminate cells with increased AVO accumulation in the top 
quadrants. In a parallel set of assays, as a negative control, untreated cells were incubated 
with bafilomycin A1 (Enzo Life Sciences), a macrolide antibiotic that inhibits the vacuolar 
type H+ATPase of AVOs, at 200 nM final concentration for 30 min before acridine orange 
staining. To confirm this result JAHA-treated MDA-MB231 cells were incubated for 48 h 
with 1 nM rapamycin (Santa Cruz Biotechnology, CA), an antibiotic that increases 
autophagosome and autolysosome formation, and the reversion of JAHA-triggered cytotoxic 
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effect was monitored by an MTT assay, as previously reported. Control cells were tested in 
parallel. 
 
3.2.8 Migration Assay 
 
MDA-MB231 cells were plated on four 22 cm
2
 culture plates at a concentration of 450.000 
cells/cm
2
. After 24 hours of incubation at 37°C the culture plate was confluent. The cells were 
then washed with 1X PBS and scraped in the middle of the plate with the scratch machine 
thereby creating an artificial "wound" or denuded area, parallel to a straight line drawn with a 
permanent marker at the bottom of the culture dish. This created a "dark line area", useful to 
simplify motile cell evaluation, which was visible as a translucent, dark background under the 
microscope. Then, the PBS was removed and the appropriate medium was added to a volume 
of 5 ml. Experimental media were:  
1. RPMI 1640; 
2. RPMI 1640 supplemented with JAHA (RPMI 1640/JAHA) to a final concentration of 
8.45 μM; 
3. RPMI 1640 supplemented with hydroxyurea (RPMI 1640/H) to a final concentration of 2 
mM; 
4. RPMI 1640 supplemented with hydroxyurea to a final concentration of 2 mM and JAHA 
to a final concentration of 8.45 μM (RPMI 1640/H/JAHA).  
MDA-MB231 cells were grown for 24 h, and at the end each five different areas of the plate 
were observed to determine the mean value and standard deviation of migrated cells into the 
denuded area. Pictures were taken with an AuxioCam MRc camera, which was connected to 
the microscope. RPMI 1640 was used as a negative control and reference value for the 
migration of cells treated with JAHA. The same media supplemented with 2 mM 
hydroxyurea, utilized to inhibit cell proliferation, were used to compare the obtained values to 
a cell growth-independent reference. Each set of experiment was performed in triplicate.  
 
3.2.9 Total RNA Isolation 
 
1x10
6 
MDA-MB231 breast cancer cells were plated in 75 cm
2 
flask and cultured in control 
conditions or with either JAHA or SAHA at 8.45 μM concentration for 18, 24 and 48 hours. 
RNA was extracted with TRI Reagent (Sigma). TRI Reagent is a quick and convenient 
reagent for use in the simultaneous isolation of RNA, DNA, and protein.  
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A single-step liquid phase separation results in the simultaneous isolation of RNA, DNA, and 
protein. This procedure is an improvement of the method reported by Chomczynski and 
Sacchi, (1987) for total RNA isolation. This product, a mixture of guanidine thiocyanate and 
phenol in a monophase solution, effectively dissolves DNA, RNA, and protein on 
homogenization or lysis of tissue sample. Cells were isolated by centrifugation and then lysed 
in 1 ml of TRI Reagent by repeated pipetting (1 ml of the reagent is sufficient to lyse 5-
10×10
6 
animal, plant, or yeast cells, or 10
7 
bacterial cells).
 
To ensure complete dissociation of 
nucleoprotein complexes, the samples were allowed to stand for 5 minutes at room 
temperature. After addition of 0.2 ml of chloroform per ml of TRI Reagent used, the samples 
were covered tightly, shaked vigorously for 15 seconds, and allowed to stand for 2-15 minutes 
at room temperature. The resulting mixture was centrifuged at 12.000 g for 15 minutes at 2-
8°C. The centrifugation separates the mixture into 3 phases: a red organic phase (containing 
protein), an interphase (containing DNA), and a colorless upper aqueous phase (containing 
RNA). The aqueous phase was transferred into a fresh tube, 0.5 ml of 2-propanol per ml of 
TRI Reagent used in sample preparation was added and the sample was to stand for 5-10 
minutes at room temperature, before centrifugation at 12.000 g for 10 minutes at 2-8°C. After 
removal of the supernatant, the RNA precipitate was washed by adding a minimun of 1 ml of 
75% ethanol per 1 ml of TRI Reagent used in sample preparation, vortexing and then 
centrifuging at 7.500 g for 5 minutes at 2-8°C. The RNA pellet was dried for 5-10 minutes 
under a vacuum and finally an appropriate volume of RNase-free water (40 l) was added and 
the RNA was solved by repeated up and down pipetting. The obtained RNA was quantified 
with a Nanodrop spectrophotometer (Thermo Scientific, USA) reading at =260 nm and its 
purity determined from the ratio of readings at 260 and 280 nm respectively, and then was 
stored at -80°C until use. mRNA-enriched samples from total RNA preparations were 
obtained using Terminator™ 5′-Phosphate-Dependent Exonuclease, a processive 5′→3′ 
exonuclease that digests RNA having a 5′ monophosphate and is ineffective on RNA having a 
5′-triphosphate, 5′-cap, or 5′-hydroxyl group. These enzymatic properties make Terminator 
Exonuclease ideal for producing mRNA-enriched samples from both eukaryotic and 
prokaryotic total RNA preparations by selectively digesting the ribosomal RNA (rRNA).  
In a sterile (RNase-free) 0.5 ml tube, the following reaction components were mixed in ice: 
 X μl RNase-free water 
 2 μl Terminator 10X Reaction Buffer A 
 0.5 μl RNase Inhibitor 
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 X μl total RNA sample (200 ng - 10 μg) 
 1 μl Terminator Exonuclease (1 U) 
 
20 μl was the total reaction volume. The reaction was incubated at 30°C for 60 minutes in a 
thermocycler (with heated lid) and terminated with the addition of 1 μl of 100 mM EDTA (pH 
8.0). The enriched mRNA was purified from excess EDTA, tRNA, 5S rRNA, and other small 
RNA species, by LiCl precipitation. Lithium chloride selectively precipitates large RNA such 
as mRNA, while small RNA such as tRNA, and nucleotides and salts (e.g., EDTA) remain in 
solution. One volume of 5 M LiCl solution was added to the sample mixed well and incubated 
in ice or at -20°C for 30 minutes. The RNA was pelleted by centrifugation in a 
microcentrifuge for 30 minutes at full speed at 4°C and, after careful removal of the 
supernatant which contains the tRNA, other small RNAs and nucleotides, washed with 70% 
ethanol to remove residual salt, and resuspended in RNase-free water or TE buffer. The 
success of the Terminator reaction was analyzed by denaturing agarose gel electrophoresis. 
The absence of 18S and 28S rRNA in the post-treatment sample indicates a successful 
reaction. 
 
3.2.10 Genomic DNA isolation  
 
The genomic DNA was purified from MDA-MB231 cells grown in control conditions or 
treated with 8.45 M JAHA for 18, 30, and 48 h. To this purpose, we used the PureLinkTM 
Genomic DNA Kit, which is based on the selective binding of DNA to silica-based membrane 
in the presence of chatropic salt. 
The following protocol was applied: 
- to prepare cell lysate, growth medium was removed, and cells were harvested by 
trypisinization and resuspended in 200 μl PBS. Twenty μl Proteinase K and 20 μl RNase 
A were added to the sample. Each sample was mixed well by brief vortexing, and 
incubated at RT for 2 min. 200 μl PureLink™ Genomic Lysis/Binding Buffer were added 
and each sample was mixed well by vortexing to obtain a homogenous solution. The 
samples were incubated at 55°C for 10 min to promote protein digestion. Two hundreds μl 
of 96-100% ethanol were added to the lysate. Each sample was mixed well by vortexing 
for 5 seconds to yield a homogenous solution; 
- to bind DNA, the obtained lysate was transferred in a PureLink™ Spin Column provided 
by the kit. The column was centrifuged at 10.000×g for 1 minute at RT. The collection 
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tube was discarded and the spin column was placed into a clean PureLink™ Collection 
Tube supplied with the kit; 
- to wash DNA, 500 μl Wash Buffer 1 prepared with ethanol were added to the column. 
The column was centrifuged at RT at 10.000×g for 1 minute. The collection tube was 
discarded and the spin column was placed into a clean PureLink™ Collection Tube. 
500 μl of Wash Buffer 2 prepared with ethanol were added to the column. The column 
was centrifuged at maximum speed for 3 minutes at RT and collection tube was discarded; 
- to elute DNA the spin column was placed in a sterile 1.5 ml microcentrifuge tube. 50 μl of 
PureLink™ Genomic Elution Buffer were added to the column. The sample was 
incubated at RT for 1 minute and centrifuged at maximum speed for 1 minute at RT thus 
recovering the purified genomic DNA. To recover more DNA, a second elution step was 
performed using the same elution buffer volume as first elution in another sterile 1.5 ml 
microcentrifuge tube. Then the column was centrifuged at maximum speed for 1.5 min at 
RT. The tube contained purified DNA. The column was removed and discarded; the 
purified DNA was stored at -20°C.  
Genomic DNA concentration was measured using a Nanodrop spectrophotometer 
(Thermo Scientific, USA). 
 
3.2.11 Reverse Transcription Reaction 
 
SuperScript™ II Reverse Transcriptase (RT) is an engineered version of M-MLV RT with 
reduced RNase H activity and increased thermal stability. The enzyme is purified to near 
homogeneity from E. coli containing the modified pol gene of Moloney Murine Leukemia 
Virus (Kotewicz et al., 1985; Gerard et al., 1986.). The enzyme can be used to synthesize 
first-strand cDNA at higher temperatures than conventional M-MLV RT, providing increased 
specificity, higher yields of cDNA, and more full-length product. It can generate cDNA up to 
12.3 kb. 
A 20 μl reaction volume was used for 250 ng of mRNA. The following components were 
mixed into a nuclease-free microcentrifuge tube:  
 
 2 μl (50 μM) random primers  
 X μl 250 ng of mRNA 
 1 μl dNTP Mix (10 mM each)  
 Sterile, distilled water to 12 μl 
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The mixture was heated to 65°C for 5 min and quickly chilled in ice. The contents of the tube 
were collected by brief centrifugation and added to: 
 
 4 μl 5X First-Strand Buffer  
 2 μl 0.1 M DTT  
 1 μl RNaseOUT™ (40 U/μl)  
 
The mixture was incubated at 25°C for 2 min and then 1 μl (200 U) of SuperScript™ II RT 
was added and mixed by pipetting gently up and down. The tubes were incubated at 25°C for 
10 min, then at 42°C for 50 min, and, at the end to inactivate the reaction, heated at 70°C for 
15 min. 
 
3.2.12 Conventional PCR reaction 
 
 
For PCR amplification, the following reagents were mixed into a 0.5 ml PCR tube (20 μl was 
the total reaction volume) in the following order: 
 
 14.5 μl water 
 2 μl RED Taq PCR Reaction Buffer 10X 
 0.5 μl Forward Primer (100 pmoli/μl)  
 0.5 μl Reverse  Primer (100 pmoli/μl)  
 1μl cDNA template 
 1μl RED Taq DNA Polymerase 
 
Cycling parameters: 
 Initialization step at 94°C for 2 minutes 
 Denature the template at 94°C for 1 minute 
 Anneal primers at 60°C for 1 minute                     25, 30 or 35 cycles of amplification  
 Extension at 72°C for 1 minute 
 Final elongation at 72°C for 5 minutes 
 
The amplified DNA was loaded directly onto an 2% agarose gel after the PCR process.  
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3.2.13 Primer Sequences used for PCR amplification  
  
 
 
 
 
 
 
 
 
                         
                                                                                      Name           
 
 
 
 
Amplicon 
Size (bp) 
 
 
 
 
 
 
 
 Ta (°C) 
 
 
 
 
Forward Primer 
Reverse Primer 
 
PKCε 
 
 
 
 
249 
 
 
 
 
 
 
 
60 
 
 
 
5’- GATCAGAAGGTCACTGCAA-3’ 
5’-GTCGTCATGGAGGATGGACT-3’ 
 
 
 
 
 
PKCι 
 
 
169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             60 
 
 
 
 
5’-TACGGCCAGGAGATACAACC-3’ 
5’-TCGGAGCTCCCAACAATATC-3 
 
 
 
 
 
 
 
 
 
 
ERGIC 
 
 
 
196 
 
 
 
 
 
 
 
 
60 
 
 
 
 
5’-GCCATGGAGTCTCTGGGATA-3’ 
5’-CCAAGTCTGAAACGACAGCA-3’ 
 
 
 
 
 
 
 
LRCH1 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                         
                                                                                                                         220 
 
 
 
 
 
 
 
 
 
                                                        60 
 
 
 
 
 
5’-GATTCGGGAGTTGGAAGTGA-3’ 
5’-CTCCTGAGTTGGTGCTGTCA-3’ 
 
 
 
 
 
 
 
 
 
RAD50 
 
 
 
 
 
 
215 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
5’-CTTGGATATGCGAGGACGAT-3’ 
5’-CCAGAAGCTGGAAGTTACGC-3’ 
 
 
 
 
MED25 
 
 
 
 
 
                                                                                                                   188 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
5’-CAGCGCCTATGAGTTTGTCA-3’ 
5’-AGTATGGGGGTGAGTTGCAG-3’ 
 
 
 
 
 
 
 
 
 
                                               NAALAD2 
 
 
 
 
 
 
 
 
229 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
5’-AAAAGGCTGGATTTGGAGGT-3’ 
5’-GGCGAAGAGATCAGTTTTGC-3’ 
 
 
 
 
 
 
 
NTRK2 
 
 
 
 
 
 
181 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
5’-AGCATGAGCACATCGTCAAG-3’ 
5’-ATATGCAGCATCTGCGACTG-3’ 
 
 
 
 
 
 
 
          Brefeldine A - 
 
 
 
 
 
231 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
5’-CGCCCTGTCTCTAAAACTGC-3’ 
5’-CTGTCTGCGTTCATCAGCAT-3’ 
 
VDUP1 
 
223 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
 
5’-TTGTTCTCCCCTTCTGCCAT-3’ 
5’-AGGGTTGGGCATCTTGATCA-3’  
 
IDI1 
 
206 
 
 
 
 
 
 
 
 
                                                         60 
 
 
 
 
 
 
 
5’-TTGGGCTGGATAAAACCCCT-3’ 
5’-ACACAGGCCTTTGTTGTTGT-3’ 
 
Gelsolin 
 
 270 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
5’-TGTGATCGAAGAGGTTCCTG-3’ 
5’-GACCAGTAATCATCATCCCA-3’  
 
Actin 
 
 
 
 
 
 
 
 
 
           51                                                                                                                                        
 
        60 
 
 
 
 
 
5’-AGG-CAC-CAG-GGC-GTG-AT-3’ 
5’-GCC-CAC-ATA-GGA-ATC-CTT-CTG-AC-3’ 
 
 
 
 
 
 
 
 
 
 
                                                              GAPDH 
 
 
414 
 
     60 
 
 
 
 
5’-CATGGAGGAGGCTGGGGCTC-3’ 
5’-CACTGACACGTTGGCAGTGG-3’ 
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3.2.14 Differential Display- PCR  
 
 
 
 
 
Differential display is a technique used to compare and identify changes in gene expression 
between cell samples. The RNA extracted from MDA-MB231 cells grown in control 
conditons or treated with 8.45 μM of JAHA was amplified using arbitrary primer as reported 
by Sokolov and Prokop, (1994). 
 
 
Their criteria used to design the primers for PCR amplification of the cDNAs were:  
 
 
1. no stop codon was present in any possible reading frame in both directions;  
2. the sequences had a minimal tendency to form internal loops;  
3. the sequences included the most commonly employed codons in mammals;  
4.  there was a minimal overlap in sequences among primers;  
5.  the GC content should be 60-70%;  
6.  there was a minimal number of glycine codons so as to avoid over-representations of the 
collagens that are abundant in many mammalian tissues 
7. primers were 13-mer or less.  
 
Primers with arbitrary but fixed sequences were used for the PCR amplification in these 
combinations: BS52 + BS54, BS54 + BS55, BS57 + BS58, BS70 + BS73, BS76 + BS78. 
 
BS52 CAAGCGAGGT 
BS54 AACGCGCAAC  
BS55 GTGGAAGCGT  
BS57 GGAAGCAGCT  
BS58 CAGTGAGCGT 
BS70 GAGCTATGGC  
BS73 CACAGTGAGC 
BS76 CTGGTCACAC  
BS78 AGCCTGTGTC 
 
For every samples the following reaction components were combined: 
 
 3 µl Stoffel buffer 10X, 
 3 µl MgCl2 25 mM, 
 0.6 µl dNTP mix (10 mM), 
 0.5 µl (25 pmoli/μl) forward primer, 
AB 
DE 
FG 
HI 
BC 
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 0.5 µl (25 pmoli/μl) reverse primer, 
 0.36 µl (10 U/μl) AmpliTaq DNA Polymerase Stoffel Fragment (Applied Biosystems), 
 1 µl cDNA, 
 H2O up to a final volume of 30 l.  
 
 
 
Cycling parameters: 
 Initialization step at 94.5°C for 3 minutes 
 Denature the template at 94.5°C for 1 minute 
 Anneal primers at 34°C for 1 minute                     45 cycles of amplification  
 Extension at 72°C for 1 minute 
 Final elongation at 72°C for 10 minutes 
 
 
 
The amplification products were examined by polyacrylamide gel electrophoresis and silver 
staining. To this purpose, a 6% non-denaturing polyacrylamide gel solution was prepared 
using the following mixture: 
- 8.55 ml 40% acrylamide solution, 
- 9 ml 2% N, N- methylene bis-acrylamide solution, 
- 6 ml 10X TBE, 
-     H2O up to a final volume of 60 ml. 
 
 
The mixture was subsequently degassed by the use of a vacuum pump. 
The glass plates (Sequi-Gel, BioRad, USA) of the electrophoresis apparatus were treated with 
specific solutions as follows: 
- the fixed glass plate with 1.5 ml silanisation solution, 
- the mobile glass plate with a binding solution composed of 5 μl γ-
methacryloxypropanyltri-methoxy-silane, 5 μl CH3COOH and 1 ml 95% ethanol. 
 
 
 
In order to prepare the bottom layer of the gel, 10 ml of the 6% polyacrilamyde solution were 
mixed with 50 μl TEMED and 50 μl 25% APS and poured over Whatman paper. The gel 
casting apparatus was assembled according to the manufacturer’s manual allowing the bottom 
layer to soak in between the two plates by capillary forces. 
Afterwards, the separation gel was prepared by combination of 40 ml of the 6% 
polyacrilamyde solution with 40 μl TEMED and 40 μl 25% APS and carefully applied by a 
syringe. Immediately upon polymerization (45-60 min), the comb was removed; the upper 
(stacking) gel was prepared as described for the bottom layer and carefully applied to the 
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casting apparatus by a syringe and the gel comb was inserted. The gel was allowed to 
polymerize overnight at RT. 
The next day, the gel comb was removed and the wells were carefully rinsed with 1X TBE to 
reduce bubble formation. Afterwards, 6 μl of PCR product were mixed with 0.6 μl of 10X gel 
loading solution and loaded. 100 or 50 bp DNA ladder (Sigma) were used as markers. 
Electrophoresis was performed at constant 2000 V and 55 W for 1 or 2 hours until the 
bromophenol blue bands run out of the gel.  
For staining of the DNA bands the following solutions were prepared: 
 Fix stop solution: 200 ml CH3COOH 10% and 1800 ml milliQ H2O up to a final volume 
of 2 l; 
 Staining solution: 1 gr AgNO3, 1.5 ml Formaldehyde 37%, and milliQ H2O up to a final 
volume of 1 l; 
 Developing solution: 30 gr Na2CO3 in 1 l of milliQ H2O. This solution was stored at 4°C 
and immediately before use 1.5 ml of Formaldehyde 37%, and 200 l Sodium thiosulfate 
(10 mg/ml) were added. 
 
After the electrophoresis and the deassembling of the gel cassette, the gel fixed on the glass 
plate was subjected to the following treatments: 
 fixation in agitation for 20 min in 1 l of Fix stop solution, 
 three washings for 2 min in milliQ H2O, 
 treatment with 1 l of Staining solution for about 30 min,  
 washing for 10 sec in milliQ H2O, 
 addition of 500 ml of Developing solution and shaking until some bands became visible 
(2-3 minutes). Addition of 500 ml of Developing solution for 2-3 min until all bands 
appear, 
 addition of 1 l Fix stop solution to block the reaction, 
 washing for at least 2 times with milliQ H2O and drying at RT prior to photography, 
 bands of interest were cut out and stored at -20°C before to use. 
 
To amplify the cDNA present in the excised bands, a PCR reaction was performed in the 
presence of Stoffel DNA polymerase and the specific primers used in DD-PCR, as described 
above. The obtained products were then subjected to various purification cycles using the kit 
described below, to obtain a single band observable after agarose gel electrophoresis. For this 
reason agarose (2 g) was dissolved in 100 ml Tris/Borate EDTA buffer 1X using TBE 10X 
(89 mM Tris-borate and 2 mM EDTA, pH 8.3) by heating in a microwave until boiling, this 
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solution was allowed to cool and ethidium bromide was added (0.5 µg/ml). Gel 
electrophoresis was carried out in a horizontal tank containing TBE buffer 1X and was run at 
80 V for 1.5 h. Thermo Scientific 6X DNA Loading Dye was used to prepare DNA markers 
and samples for loading on agarose gel. It contains two different dyes (bromophenol blue and 
xylene cyanol) for visual tracking of DNA migration during electrophoresis. The 50 bp DNA 
Ladder (Invitrogen) was used for precise qualitative and approximate quantification of DNA 
mass. After the electrophoretic run, the DNA was checked under UV light. 
Subsequently, to purify the PCR product from the gel we used the Montage
TM
 PCR 
Centrifugal Filter Devices (MILLIPORE): it simplify the purification of PCR products by 
allowing for concentration and removal of primers and unincorporated dNTPs prior to use of 
DNA in subsequent applications. 
The following protocol was applied: 
 50 l PCR reaction and 350 l of distilled water were pipetted into sample reservoir to a 
final volume of 400 l, 
 the Montage PCR unit was spinned at 1000xg for 15 min, 
 the sample reservoir was placed upright into a clean vial and 20 l of distillated water 
were added to the purple end of reservoir, avoiding to touch the membrane surface, 
 to recover the purified DNA the reservoir was inverted into clean vial and spinned at 
1000xg for 2 min. 
 
To remove any unconsumed dNTPs and primers remaining in the PCR product mixture, 
which could interfere with the sequencing reaction, the PCR products obtained by 
amplification were purified by ExoSAP-IT method that involves the use of two hydrolytic 
enzymes, Exonuclease I and Shrimp Alkaline Phosphatase, to remove the unwanted dNTPs 
and primers. In this case, 5 μl of PCR product and 2 μl of Exosap were mixed and incubated 
at 37°C for 15 min. Then, to inactivate Exosap the samples were heated to 80°C for 15 min. 
After that the PCR products were sequenced by the sequencing service of BMR Genomics 
(Padova, Italy). 
 
3.2.15 Real Time Polymerase Chain Reaction  
 
Total RNA was extracted from control and treated MDA-MB231 cells and first-strand cDNA 
was synthesized as already reported mRNA expression levels were determined by quantitative 
real-time PCR, with Power SYBR Green PCR Master Mix (Applied Biosystems Philadelphia, 
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PA, USA) in a 7300 Real Time PCR system (Applied Biosystem). Actin was used as internal 
control.  
PCR data obtained by the instrument software were automatically analysed by the Relative 
Quantification Study Software (Applied Biosystem ) and expressed as target/reference ratio. 
The cycle conditions for real-time PCR were 95°C for 10 min, followed by 40 cycles of 95°C 
for 1 min, and 60°C for 1 min.  
 
3.2.16 Methylation-Sensitive Restriction Endonucleases Multiplex-PCR 
 
 
 
 
 
 
 
 
Genomic DNA was obtained from control and treated MDA-MB231 cells as already reported. 
The methylated CpG islands were detected by MeSAP-PCR, carried out according to Liang et 
al., (2002) with some modifications (Naselli et al., 2014). Briefly, DNA from MDA-MB231 
breast cancer cells (2 µg) was digested in a total volume of 10 µl for at least 16 h, at 37°C, 
with 1 µl 10 U of Afa I restriction endonuclease (Invitrogen) (single digested DNA, SDD), 2 
µl 10X Buffer T, 2 µl 0.1% BSA and steril water to 10 µl. The cleavage site of the enzyme is: 
(GT*AC).  
Then, one half of SDD digested was further treated with 0.5 µl 10 U HpaII, a methylation-
sensitive restriction endonuclease unable to cut DNA if methylated cytosine is present in its 
recognition site (CG*GG) at 37°C for 16 h (double digested DNA, DDD), 1.2 µl Buffer 10X 
and sterile water to 12 µl. SDD and DDD were heat inactivated for 20 min at 65°C and 
separately amplified by Arbitrarily-Primed PCR using two subsequent amplification cycles, 
AP1-M and AP2-M, in a T1 Plus Thermocycler (Biometria, Gottingen, Germany). In the 
AP1-M (low stringency cycle), a permissive annealing temperature, a high salt and primer 
concentration were set to allow arbitrary primer annealing to the best matches in the template 
with the highest preference for all the genomic CpG sites since they are provided with a 3’ tail 
complementary to these sites. The reproducibility of the reactions was ensured as all 
experiments were conducted using the same rates of buffer reaction. 
 
PCR was performed in a total volume of 25 µl under the following conditions: 
 500 ng Genomic DNA  
 2.5 µl 21-mer arbitrary primer (5’-AACTGAAGCAGTGGCCTCGCG-3’) 10 µM  
 2 µl dNTPs 0.2 mM 
 1.6 µl Taq DNA polymerase recombinant (Invitrogen) 0.8 U  
 2.5 µl Buffer 10X  
 2 µl MgCl2 50 mM 
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 Cycle profile was:  
 
 
 
 
 
 
 
A Cycle 94°C 5 min 
 
4 Cycles at low 
stringency conditions 
94°C 30 sec 
40°C 60 sec 
72°C 90 sec 
 
AP2-M (high stringency cycle), runs immediately after AP1-M. Reaction mixture consisting 
of 75 µl of: 
 
 
 
 
 
 7.5 µl Buffer 10X  
 6 µl MgCl2 50 mM 
 2 µl dNTPs 0.2 mM  
 0.5 µl Taq DNA polymerase recombinant (Invitrogen) 2.5 U 
 H2O up to a final volume of 75 l.  
was added to 25 µl of AP1-M mix, immediately before AP2-M cycle.  
 
 
 
 
 
 
 
Cycle profile was:  
 
 
 
 
A Cycle 94°C 60 sec 
     4 Cycles at low 
stringency conditions 
60°C 60 sec 
72°C 2 min 
72°C    90sec 
 
The amplified DNA was resolved by non-denaturating 6% acrylamide-bisacrylamide (29:1 
ratio) gel electrophoresis preparated using the following mixture:  
 
 
 
 
 
- 2.5 ml 10X TBE  
- 5 ml 30% acrylamide-bisacrylamide (29:1 ratio) 
- 600 µl APS 10%  
- 11.3 µl TEMED 
- H2O up to a final volume of 25 ml. 
 
 
 
 
 
DNA fingerprinting was stained with Gel Red nucleic acid Gel Stain 3X submitted to 
densitometric scanning and analysed with the SigmaGel image analysis software (Jandel 
Scientific, San Rafael, CA, USA). 
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3.2.17 SDS-PAGE and western blotting analysis  
 
 
 
 
 
 
1x10
6 
MDA-MB231 breast cancer cells were plated in 75 cm
2 
flask and treated with 8.45 μM 
JAHA for 18, 24, and 48 h to detect LC3, p62/Sequestosome 1, and 18, 30, 48 h to detect 
Erk1/2, p-Erk1/2, Akt, p-Akt and DNMT1.  
Cells were washed once in PBS, isolated by centrifugation and lysed in a lysis buffer 
containing 7 M Urea, 2% CHAMPS, 1% IPG Buffer, 10 mM DTT, PMSF protease and 
phosphatases inhibitor cocktail (Sigma) 1X. The lysates were centrifuged at 1.000 rpm for 1 
min at 4°C. Protein concentrations were estimated by Bradford assay (Bio-Rad, Italy). 
Twenty μg of proteins for LC3, p62/Sequestosome 1, Erk1/2, p-Erk1/2, Akt, p-Akt and 50 μg 
of proteins for DNMT1 were denatured by boiling samples in 0.05% SDS and sample buffer 
[0.5 M Tris-HCl (12.5%), pH 6.8, (2%) SDS, (10%) glycerol, (5%) β-mercaptoethanol, 
bromophenol blue (0.05%)] for 3 min before electrophoresis. To detect LC3, 
p62/Sequestosome 1, Erk1/2, p-Erk1/2, Akt and p-Akt, proteins were subjected to 13% SDS-
PAGE [Acrylamide (13%), Bis-Acrylamide (0.26%), Tris-HCl 1.5 M pH 8.8 (25%), SDS 
(0.1%), Ammonium persulphate (0.1%), Temed (0.04%)], with a 3% acrylamide upper gel 
[Tris-HCl 0.5 M pH 6.8 (50%), Acrylamide (3%), Bis-Acrilammide (0.08%), Ammonium 
persulphate (0.1%), SDS (0.1%), Temed (0.08%)]. To detect DNMT1, proteins were 
subjected to 10% SDS-PAGE [Acrylamide (10%), Bis-Acrylamide (0.2 %), Tris-HCl 1.5 M 
pH 8.8 (25%), SDS (0.1%), Ammonium persulphate (0.1%), Temed (0.04%)], with a 3% 
upper gel [Tris-HCl 0.5 M pH 6.8 (50%), Acrylamide (3%), Bis-Acrylamide (0.08%), 
Ammonium persulphate (0.1%), SDS (0.1%), Temed (0.08%)]. Gel electrophoresis was 
carried out in a vertical tank containing running buffer [Tris (0.6%), Glycine (2.88%), SDS 
(0.1%)] and was run at 200 V for 3 h. 
After electrophoresis, proteins were transferred to nitrocellulose membranes (Hybond C, 
Amersham) using a (Novablot equipment Pharmacia) in transfer buffer [Tris (0.29%), 
Glycine (1.44%), Methanol (20%)] at 200 mA for 1h. To detect DNMT1 the transfer was 
increased to 2 hours, for its higher molecular weight (183 kDa). The gels were stained for 30 
min with 0.5% Coomassie Blue (LKB BROMMA) in 50% methanol and 10% acetic acid. 
Then the gel was treated with a destaining solution (50% methanol, 10% acetic acid), with 2 
washes of 10 min each. A second solution (20% methanol, 10% acetic acid) was used for total 
destaining. The complete transfer was assessed using Ponceau red staining. The nitrocellulose 
filter was treated for two minutes with 3% TCA containing 0.2% Ponceau red, and then 
washed and destained with TBS-T [NaCl (150 mM), Tris-HCl pH 7.4 (100 mM) Tween-20 
(0.05%)].  
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After 2 h of blocking with 5% non-fat dry milk in TBS-T, or in BSA, the membranes were 
incubated with the primary antibodies overnight at 4°C. The following antibodies were used: 
rabbit polyclonal anti-LC3 (L8918, Sigma, 1:1000 in 5% milk), anti-p62/SQSTM1 (P0068, 
Sigma, 1:1000 in 5% milk), anti-Erk1/2 rabbit (ab17942, Abcam, 1:500 in 5% milk), anti-
AKT rabbit (9272, Cell Signaling, 1:750 in 5% BSA), anti- p-Erk1/2 rabbit (9101, Cell 
Signaling, 1:750 in 5% BSA), anti-p-AKT rabbit (SC-7985-R, Santa Cruz, 1:750 in 5% BSA) 
anti DNMT1 rabbit (SAB2106406, Sigma, 1:250 in 5% milk). After 5 washing with TBS-T 
for 5 min, for Erk1/2, p-Erk1/2, Akt, p-Akt and DNMT1 detection, the membranes were 
incubated with rabbit secondary antibody (anti-IgG HRP horseradish peroxidase-conjugated, 
NA934V, GE Healthcare Life Sciences, 1:2500 in TBS-T) for 60 min at room temperature. 
Then, after three washing: with TBS-T and two washings with TBS for 5 min each, the 
reaction was visualized in a Chemidoc XRS (Bio-Rad) after treating the membrane with the 
two development solutions provided by Western ImmunStar™ C™ Substrate Kit. For LC3 
and p62/SQSTM1 detection, the membranes were incubated with secondary alkaline 
phosphatase-conjugated antirabbit IgG (Fc) antibody (S373B, Promega, Madison, WI), 
followed by incubation with 5-bromo-4-chloro-3′-indolyphosphate p-toluidine salt/nitro-blue 
tetrazolium chloride (BCIP/NBT) solution (Sigma).  
The membranes were stripped with a stripping buffer (1 M Tris HCl pH 6.8, SDS 10%, β-
mercaptoethanol 50 mM) for 30 min at 60°C. The data were appropriately normalized to actin 
by reprobing the filter with an antibody directed against actin (A5060, Sigma, 1:500 in 5% 
milk). Scanning densitometry of the bands were performed with the Quantity One software. 
Each Western experiment was performed in triplicate. 
 
3.2.18 Liquid chromatography-tandem mass spectrometry analysis 
 
 
 
 
1x10
6
cells were plated in 75 cm
2 
flasks, and allowed to adhere overnight. Then, the cells were 
treated with either JAHA or SAHA at 8.45 µM concentration or with the vehicle (DMSO) for 
18, 24, and 48 hours. Detached with 0.05% trypsin-EDTA and collected by brief 
centrifugation. The cellular pellet was dissolved in a solubilization buffer (0.1M Tris HCl pH 
8, EGTA 25 mM, 4% SDS, protease inhibitors cocktail (Sigma) 1X. Then samples were 
sonicated, boiled for 3-5 min and clarified by centrifugation for 15 min at max speed after 
which the supernatant was collected. The proteins were precipitated using 5 volumes of cold 
acetone (-20°C), centrifuged at 13.000 rpm for 10 min at 4°C and resuspended in SDS 0.1% 
before sonication. The protein samples were quantified using BCA assay kit (Thermo 
Scientific) and 5 g of proteins were used for tryptic digestion and protein identification for 
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quantitative analysis whereas 24 g for qualitative analysis. The solubilized proteins were 
digested overnight with sequencing grade modified trypsin (Promega, V5111, 0.01 μg per 
1 μg of protein) and the reaction was quenched by adding 0.01% trifluoroacetic acid. 
The peptidic mixtures were analyzed by LC-MS-MS/MS (liquid chromatography coupled to 
tandem mass spectrometry) using Nano-Acquity (Waters) LC system and Orbitrap Velos 
mass spectrometer (Thermo Electron Corp., San Jose, CA) (figure 3.1). Prior to the analysis, 
proteins were subjected to standard “in-solution digestion” procedure during which proteins 
were reduced with 100 mM DTT (for 30 min at 56°C), alkylated with 0.5 M iodoacetamide 
(45 min in dark room at room temperature) and digested overnight with trypsin (sequencing 
Grade Modified Trypsin, Promega V5111). The mixtures were applied to RP-18 precolumns 
(nanoACQUITY Symmetry® C18-Waters 186003514) using water containing 0.1% TFA as 
mobile phase and then transferred to nano-HPLC RP-18 column (nanoACQUITY BEH C18-
Waters 186003545) using an acetonitrile gradient (0%-35% AcN in 180 minutes) in the 
presence of 0.05% formic acid with the flow-rate of 250 nl/min. Column outlet was directly 
coupled to the ion source of the spectrometer working in the regime of data dependent MS to 
MS/MS switch. A blank run ensuring lack of cross contamination from previous samples 
preceded each analysis. The acquired raw data were processed by Mascot Distiller followed 
by Mascot Search (Matrix Science, London, UK, on-site license) against Human database. 
Search parameters for precursor and product ions mass tolerance were 20 ppm and 0.6 Da, 
respectively, enzyme specificity: trypsin, missed cleavage sites allowed: 0, fixed modification 
of cysteine by carbamidomethylation and variable modification of methionine oxidation. 
Peptides with Mascot Score exceeding the threshold value corresponding to <5% False 
Positive Rate, calculated by Mascot procedure, and with the Mascot score above 30 were 
considered to be positively identified. 
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Figure 3.1. Schematic diagram of the LTQ Orbitrap Velos MS instrument with three new hardware 
implementations. A, the stacked ring ion guide (S-Lens) increases the ion flux from the electrospray ion source 
into the instrument by a factor 5–10. B, the dual linear ion trap design enables efficient trapping and activation in 
the high-pressure cell (left) and fast scanning and detection in the low pressure cell (right). C, the combo C-trap 
and HCD collision cell with an applied axial field with improved fragment ion extraction and trapping 
capabilities. (http://planetorbitrap.com) 
 
3.2.19 Bioinformatic Analysis 
 
The acquired MS/MS raw data files were processed to produce peak lists with Mascot 
Distiller software (version 2.2.1, Matrix Science). The resulting ion lists were searched using 
the Mascot search engine (version 2.2.03, Matrix Science) against a database comprising all 
human protein entries from the Sprot (540.732 sequences) and their reversed versions.  
 
Mascot 
 
Mascot is a popular web-based tool from Matrix Science for performing rapid, accurate, 
online MS analysis of peptides and proteins that supports 3 kinds of analyses: 
- Peptide Mass Fingerprinting (PMF) 
- Sequence (tag) querying 
- MS/MS Ion searches 
 
The search parameters were as follows: enzyme specificity, trypsin, variable modifications, 
oxidation (M) and protein mass, unrestricted. The peptide and fragment ion mass tolerances 
used were 20 ppm and 0.6 Da respectively. Peptides with Mascot score exceeding the 
threshold value corresponding to <5% false positive rate (figure 3.2), calculated by Mascot 
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procedure, were considered to be positively identified. At least two peptides for protein with 
score above the threshold were required for identification.  
  
 
Figure 3.2. Peptide score distribution. 
Ions score is −10 log(P), where P is the 
probability that the observed match is a 
random event. Individual ions scores 
>18 indicate identity or extensive 
homology (p<0.05). 
 
 
 
 
Program for qualitative proteomic analysis MScan  
 
This is a program designed for the analysis of qualitative data, operating on the basis of files 
generated by the database system Mascot containing a list of peptides and proteins identified 
in the samples (http://www.proteom.ibb.waw.pl). The statistical significance of peptide 
identifications was assessed estimating the q-value for each peptide spectrum match (PSMs) 
in the data set. Only PSMs with q-values of ≤0.01 and proteins represented by at least two 
peptides identified were regarded as confidently. Proteins identified by a subset of peptides 
were excluded from analysis, and proteins matching the same set of peptides were clustered 
into single groups. Mscan software remove the sequence not selected and the random 
sequence (RS) using a FDR. The program is also responsible for the preparation of data for 
quantitative analysis (figure 3.3). 
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Figure 3.3.  Example of Mscan analysis. 
 
The basic functions of the program were: 
 Divide the sample into groups reflecting different experimental conditions, of the list of 
peptides and proteins identified.  
 Access at the Mascot informatios and more information on additional parameters such as 
(theoretical retention time, isoelectric point, hydrophobicity, isotopic pattern) and proteins 
informations such as (coverage degree, theoretical distribution of peptides with proteolytic 
enzyme selected).  
 Control of technical quality measurement in the spectrometer based on the parameters of 
distributions of the masses, retention times and the isoelectric points of the peptides. 
 Standardisation of timing waveforms chromatographic samples, aimed at reducing the 
adverse effects of instability in the parameters of the HPLC system. 
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 Estimation of the percentage of false positive identification of peptides and determination 
of q-value (being a measure of the reliability of the identification peptides) based on the 
type of database search target/decoy. 
 Elimination from the resulting set of proteins and peptides that do not meet user-defined 
criteria for the reliability of identification, prevalence in the studied samples, the error of 
weight derogation from the expected retention time and theoretical isoelectric point and a 
number of other parameters. 
 Reduced redundancy by combining the results of the identification of a group of proteins 
(clustering) sequences having substantial homology. 
 Ability to interface with generally available databases to obtain additional information 
about the identified proteins and download their sequences by directly supporting the 
database of NCBI, SwissProt and SGD.  
 
Program for quantitative proteomic analysis 
 
 
 
 
 
 
 
To perform the quantitative analysis a MSparky software tool for quantitave proteomic 
analysis was used. Starting from the raw data, MSparky was able to calculate the relative 
intensities of reporter ions from a specific identified tandem mass spectrum. Protein 
intensities resulted from the average of the single reporter ion intensities, obtained for each 
peptide associated to a specific protein. The program is based on the representation of LC-MS 
data in the form of two-dimensional maps and models of theoretical spectra of peptide ions. 
 
The basic functions of the program were: 
 
 Visualization of high-quality two-dimensional representation of the LC-MS analysis of 
multiple samples simultaneously (figure 3.4). 
 Automatic search for the position of the mass spectra of peptides in the mass spectra of 
the solid test samples. The position of the peptides is based on the degree of fit of 
theoretical models of spectra to the experimental data. As a result of the search algorithm 
to each peptide is assigned a quantitative parameter defined as the volume of the fitted 
model. 
 Automatic or manual verification of the results. 
 Processing (normalization) and visualization of the numerical value of the expression. 
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Figure 3.4.  Example of MSparky analysis. 
 
The Diffprot program allows the statistical analysis of quantitative data from proteomic 
experiments performed without isotopic labeling or iTRAQ-labeling method. The tool is 
particularly well-suited to the analysis of data from a small number of samples and exhibits a 
high resistance to errors that may result from incorrect identification of peptides. 
The basic functions of the program were: 
 
 Determination of protein concentration ratios in the compared groups of samples based on 
quantitative measurements of peptides. 
 Determination of the statistical significance of protein concentration ratios using non-
parametric permutation test, which determines the distribution of the test statistics at the 
truth of the null hypothesis based on random changes in assignments of samples to groups 
and peptides to proteins. Resulting p-value are corrected for multiple testing to control the 
FDR (False Discovery Rate). 
 Normalization of quantitative values derived from separate measurements using a linear 
scale. 
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 Elimination from the data set of selected peptides that do not meet the criteria of the 
quality or intensity of the identification of the observed peaks and the proteins represented 
by too few peptides. It is also possible to exclude from the analysis of proteins selected by 
the user (e.g. Known contaminating proteins). 
 Grouping of proteins with a high degree of commonality of peptides. 
 
It is possible to obtain from the analysis with this software a list of proteins that appear to be 
differentially expressed in the control and treated. For each was calculated R value (the 
control and treated intensities ratio). 0<R value <1 down-regulation (control/treated ratio) or 
1<R value <+∞ up-regulation (control/treated ratio). Another parameter, F give information 
about the fold changing. Data were displayed as the mean ± SE of independent triplicate 
experiments. Q-values less than 0.05 were assigned as statistically significant. 
 
 
3.2.20 Statistical Analysis 
 
Statistical analysis was applied using the Microsoft Office Programme Excel 2007. The 
average mean value with the respective standard deviation for each set of triplicate 
experiments was plotted in a graph for the final evaluation. Results are given as mean ± SD. 
Data were analyzed using software-assisted analysis of variance (Sigma Stat v.2; SPSS, 
Chicago, IL, USA) and p<0.05 was taken as the minimal level of statistical significance. 
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4. Results 
 
 
 
 
 
 
4.1 Effect of JAHA and homo-JAHA treatment on cell 
viability/proliferation 
 
In a first set of experiments, we checked the effect of dose- and time-dependent incubation 
with JAHA and homo-JAHA (figure 4.1) on MDA-MB231 cell viability via MTT assay. As 
shown in Figure 1B, when cells were exposed for 72 h to JAHA, this compound caused death 
in a concentration dependent manner with an IC50=8.45 μM, and such concentration was 
chosen for all of the subsequent biochemical experiments. On the other hand, after 72 h of 
treatment, homo-JAHA at the highest concentration used (100 μM) reduced cell viability only 
to 63 ± 1.8%. The same concentration of either JAHA and homo-JAHA determined a 
decrease of cell viability to 83.9 ± 5.1 and 83.15 ± 9.7% at 24 h of incubation and 66.4 ± 6.7 
and 61.54 ± 2.09%, respectively. We showed that JAHA is more active than homo-JAHA, for 
this reason we used only JAHA for the subsequent experiments. 
 
Figure 4.1. JAHAs and their 
effect of 72 h of incubation 
on the viability of MDA-
MB231 cells. (A) Structure 
of JAHA and homo-JAHA. 
(B) Dose-response curves for 
JAHA and homo-JAHA from 
triplicate MTT assays. The 
results are expressed as 
means ± SEMs.  
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4.2 JAHA-induced non-apoptotic death on MDA-MB231 cells 
 
Phase-contrast microscopical observation of MDA-MB231 cells treated with 8.45 μM JAHA 
showed visible effects of cell death such as decreased cell number and the presence of 
rounded and floating cells, with respect to the firmly spread control cell preparations (figure 
4.2). 
 
 
 
    
 
 
 
    
 
Figure 4.2. Representative phase contrast micrographs of control and 8.45 μM JAHA-treated cells showing 
changes in cell number and morphology after exposure to JAHA. Bar=10 μM. 
 
Therefore, we performed a set of experiments aimed to get more detailed data on the 
molecular mechanism of JAHA-induced toxicity on MDA-MB231 cells. First, samples of 
control and JAHA-treated cells were submitted to annexin VFITC/propidium iodide (PI) 
staining and flow cytometric measurement to investigate the effect of JAHA on 
phosphatydilserine externalization, as a hallmark of induction of apoptosis, after short-term (5 
h), and longer term (24 and 48 h) treatments. As shown in figure 4.3, JAHA treatment 
appeared to elicit a non apoptotic cytotoxic effect as indicated by the increase of the 
percentage of necrotic cells in both top quadrants at 48 h of exposure and the almost total 
absence of apoptotic annexin+/PI- cells in the bottom right quadrant at all times of 
investigation.  
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Figure 4.3. Flow cytometric analysis of 
control and JAHA-treated MDA-MB231 
cells stained with annexin V-FITC and PI 
for detection of phosphatydilserine 
externalization after 5, 24 and 48 h-
exposure. The percentage indicated in the 
four quadrants in each frame is referred to 
necrotic annexin
-
/PI
+
 and annexin
+
/PI
+
 cells 
(both top quadrants), apoptotic annexin
+
/PI
-
 
cells (bottom right quadrant) and normal 
annexin
-
/PI
-
 cells (bottom left quadrant). 
Upon treatment, apoptotic cells never 
accounted for more than 0.59% of the cell 
population, whereas the percentage of 
necrotic cells showed an increase at long-
term exposure. 
 
 
 
 
4.3 Alterations of MDA-MB231 cell cycle cells after JAHA 
treatment 
 
In order to check which kind of perturbation was induced by JAHA treatment on MDA-
MB231 cell cycle, cells treated with JAHA for 24 and 48 h were stained with PI and subjected 
to flow cytometric analysis of the distribution of cell cycle phases. Figure 4.4 shows that, if 
compared to controls, exposure to JAHA was linked with a higher percentage of cells in the 
subG0 fraction (66.22 and 47.20% vs. 47.86 and 35.11%, respectively, at 24 and 48 h), 
consistent with an increase of damaged and fragmented cells due to compound toxicity more 
prominent at earlier times, a pronounced decrease of the S phase fraction (6.68 and 8.28% vs 
19.07 and 20.39%, respectively, at 24 and 48 h) and also of the 24 h G0/G1 phase fraction 
(11.55 vs. 21.17%). Noteworthy, flow cytometric analysis also showed an increase of the 48 h 
G2 phase fraction (15.53 vs 8.23%), indicative of the acquisition of the inability to proceed 
through the G2/M transition upon prolonged incubation.  
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Figure 4.4.  
DNA profiles of control (darker in 
the background) and JAHA-treated 
(lighter superimposed) MDA-MB231 
cells after 24 and 48 h of exposure. 
Cell cycle distribution is reported in 
the annexed tables for both cell 
samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 JAHA-induced decrease of MMP in MDA-MB231 cells 
 
To detect variations of MMP after exposure to JAHA, we used the JC1 probe that is 
selectively uptaken into mitochondria, undergoing a fluorescence emission shift from green 
(~529 nm) to red (~590 nm) in the case of intact MMP, whereas in the case of mitochondrial 
depolarization, a decrease in the red/green fluorescence intensity ratio can be observed. As 
shown in figure 4.5, flow cytometry analysis puts in evidence the time-dependent loss of the 
MMP in JAHA-treated cells, the percentage of low red-emitting cells (bottom quadrants) 
being about 9% after 24 h of exposure and increasing up to about 36% at 48 h of incubation, 
versus 2 and 5% of control cells, respectively.  
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Figure 4.5. Analysis of MMP in control and JAHA-treated MDA-MB231 cells. Flow cytometric analysis of 
control and JAHA-treated MDA-MB231 cells stained with JC1 after 24 and 48 h-exposure. The percentages 
indicated in the bottom quadrants in each frame are referred to low red-emitting cells that underwent to 
dissipation of MMP. 
 
4.5 JAHA-induced increase in reactive oxygen species production 
in MDA-MB231 cells 
 
The ability of JAHA to affect mitochondrial metabolism was also assessed through evaluation 
of ROS production using a commercial kit, which differentiates between total ROS and 
superoxide. As shown in figure 4.6 A, exposure to JAHA determined an early 3-fold increase 
of total intracellular ROS within 24 h of incubation; on the other hand, such upregulation of 
total ROS was not recorded at 48 h of treatment. In addition, although the superoxide-positive 
fraction of MDA-MB231 cells treated with JAHA for 48 h was higher than that of controls 
(19.69 vs. 4.05%), the value was consistently less than half of that obtained with the 
pyocyanin-treated sample as positive control, thereby indicating that the observed 
upregulation of superoxide ion was not significant (data not shown). To check whether the 
observed ROS up-regulation could be involved, at least in part, in the onset of JAHA-
triggered cytotoxicity, MDA-MB231 cells were coincubated with 8.45 μM JAHA and the 
phenolic antioxidant BHT at increasing concentrations. The results shown in figure 4.6 B 
demonstrate that the co-treatment was capable of reversing the decrease in cell number 
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recorded with JAHA-only treatment, with 25 and 50 μM BHT concentrations, respectively, 
inducing a comparable and more pronounced cell growth than that of the untreated control.  
 
Figure 4.6. Effect of JAHA treatment on ROS 
production by MDA-MB231 cells and its 
involvement in the cytotoxic effect. A) Flow 
cytometric analysis of control and JAHA-treated 
MDA-MB231 cells stained with two color ROS 
detection reagents, after 24 and 48 h-exposure. 
The percentage indicated in the four quadrants in 
each frame is referred to superoxide only 
overproducing cells (top left quadrant), total ROS 
overproducing cells (bottom right quadrant) and 
total ROS/superoxide overproducing cells (top 
right quadrant). Upon treatment, MDA-MB231 
cells undergo a threefold up-regulation of total 
ROS within 24 h of exposure. The up-regulation 
of superoxide ion recorded at 48 h is not 
significant, the value being less than half of that 
of pyocyanin-treated sample, used as positive 
control (data not shown). B) MTT assay of 
control (A) and JAHA-treated (B-E, black bars) 
MDA-MB231 cells assayed in parallel with cells 
co-incubated with 8.45 µM JAHA and BHT at 5, 
10, 25 and 50 µM concentrations (B-E, grey 
bars). The culture was grown for 24 h and the 
assay was made in triplicate. The results are expressed as mean ± s.e.m. * indicates p<0.05. BHT at 25 and 50 
µM concentrations induced a reversal of the cytotoxic effect exerted by JAHA.  
 
4.6 Autophagy inhibition in MDA-MB231 breast cancer cells 
treated with JAHA 
 
We checked whether JAHA determined a modification in the amount of autolysosomes, a 
hallmark of autophagy, through staining with acridine orange, a cell-permeable fluorescent 
dye that can be sequestered by acidic compartments after uptake and protonation. Figure 4.7 
shows that JAHA-treated cells underwent a consistent reduction of AVO accumulation 
between 24 and 48 h of exposure and that such a decrease was comparable to that observed 
when cells were incubated with 200 nM bafilomycin A1, a well-known inhibitor of 
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autolysosome maturation, (Yamamoto et al., 2008) as a negative control. Autophagy 
modulation by JAHA treatment was also monitored via molecular markers through 
immunoblot analysis.  
 
Figure 4.7. Effect of JAHA treatment on AVO accumulation in MDA-MB231 cells. Flow cytometric analysis of 
control, JAHA, and bafilomycin A1-treated MDA-MB231 cells stained with acridine orange, after 24 and 48 h-
exposure. The percentage indicated is referred to AVO-positive cells. JAHA treatment induced a consistent 
reduction of AVO accumulation between 24 and 48 h of exposure, comparable to that observed when cells were 
incubated with autophagy-inhibitor bafilomycin A1. 
 
In particular, we checked (i) the conversion of microtubule-associated protein light chain 3 
(LC3) from its cytosolic form (LC3-I) to its autophagosome-associated lipidated form (LC3-
II), which differs for its lower molecular mass and can be discriminated through SDS-PAGE, 
(Mizushima et al., 2007) and (ii) the changes in the accumulation levels of p62/SQSTM1, a 
receptor for ubiquitinated proteins that selectively delivers them into the autophagosome and 
is known to be a specific degradation substrate for autophagy. After the Western blot, the 
densitometry of the immunostained bands was performed with the ImageJ software. The 
immunoblot in Figure 4.8 A shows that LC3-II was decreased in MDA-MB231 cells after 48 
h of exposure to JAHA. In particular, figure 4.8 B, C reports the densitometric analyses 
referred to the LC3-II/LC3-I ratio and also to the LC3-II band only, as suggested by the 
advice of Mizishuma and Yoshimori, (2007). In both cases, although the difference between 
control and exposed cells was not evident at 24 h, apart from a faint decrease of the band 
intensity ratio, the increase of the duration of incubation with JAHA up to 48 h resulted in a 
reduction of both the LC3-II/LC3-I ratio and the intensity of LC3-II band down to about 52 
Chapter 4: Results 
 
77 
 
and 71%, respectively, thus confirming the flow cytometric data. Further evidence of JAHA-
induced autophagy down-regulation was also given by the immunoquantitation of 
p62/SQSTM1. In fact, as shown in figure 4.8 D the p62/SQSTM1 amount in JAHA-treated 
cells normalized for that of actin increased by about 50% after 48 h of incubation, whereas it 
remained constant at 24 h of culture.  
 
 
Figure 4.8. Effect of JAHA treatment for 24 and 48 h on autophagosome formation in MDA-MB231 cells. A) 
SDS-PAGE and Western blotting for LC3-I and -II of whole-cell lysates of samples grown in control conditions 
or exposed to 8.45 µM JAHA for 24 and 48 h. Beta-actin was used as loading control. B) and C) Histograms 
showing the LC3-II/LC3-I ratio (B) and the normalized LC3-II band intensity (C) of control (black bars) and 
JAHA-treated (grey bars) MDA-MB231 cells after 24 and 48 h of culture. The results are expressed as mean ± 
s.e.m. of triplicate experiments. * indicates p<0.05. D) SDS-PAGE and Western blotting for p62/SQSTM1 of 
whole-cell lysates of samples grown in control conditions or exposed to 8.45 μM JAHA for 24 and 48 h. Beta-
actin was used as loading control.  
 
Interestingly, when we evaluated the amount of LC3-I, LC3-II, and p62/SQSTM1 after 
shorter term JAHA treatment, that is, at 18 h from cell plating, we found an increase of the 
LC3-II/LC3-I ratio by about 62% and a reduction of p62/SQSTM1 down to about 20% (figure 
4.9), consistent with an early autophagy induction, which is then followed by an arrest of the 
* 
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autophagic flux over 24-48 h of treatment. To check whether inhibition of the autophagic 
process could account, at least in part, for the observed JAHA-triggered lethal effect on 
MDA-MB231 cells, cells were coincubated with 8.45 μM JAHA and increasing 
concentrations of rapamycin (sirolimus), an antibiotic acting as autophagy promoter via 
inhibition of the mammalian target of rapamycin (mTOR), a serine-threonine kinase that 
plays a key role in regulating fundamental cellular activities, such as growth, proliferation, 
cytoskeletal architecture, transcription, and translation. When MDA-MB231 cells were 
coincubated with 8.45 μM JAHA and 1 nM rapamycin, by analogy with BHT treatment, we 
found that also this cotreatment was capable of reversing the JAHA triggered decrease in cell 
number figure 4.10, thereby revealing autophagy inhibition as a further aspect, supplementary 
to early ROS production, involved in the cytotoxic effect exerted by the HDACi under study 
on MDA-MB231 breast tumor cells. 
 
 
 
Figure 4.9. Effect of JAHA treatment for 18 h on autophagosome 
formation in MDA-MB231 cells. Histograms showing the LC3-
II/LC3-I ratio (A) and the normalized p62/SQSTM1 band intensity (B) 
of control and JAHA-treated cells. 
 
 
 
 
 
 
 
Figure 4.10. Effect of rapamycin co-treatment on JAHA-
induced cytotoxicity on MDA-MB231 cells. MTT assay of 
control, JAHA-treated and JAHA/rapamycin co-treated 
MDA-MB231 cells. The culture was grown for 48 h and the 
assay was made in triplicate. The results are expressed as 
mean ± s.e.m. * indicates p<0.05. Rapamycin at 1 nM 
concentration induced a reversal of the cytotoxic effect 
exerted by JAHA. 
 
 
 
  * 
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4.7 Inability of JAHA to affect MDA-MB231 cell motile behaviour 
 
A wound assay was set up and performed, to evaluate the effects of migration on MDA-
MB231 breast cancer cells treated with JAHA. Cultures were grown to a confluency of 80-
90%. A wound was created using the scratch machine (figure 4.11). The migration of the cells 
treated with JAHA into the denuded area of the artificial wound was evaluated. The migrating 
cells were distinguishable from non-migrating cells and showed directional change towards 
the denuded area.  
          
Figure 4.11. The scratch machine. A) The scratch machine is shown with an adjusted cell dish. B) Head of the 
scratch machine is shown to visualise the scraper. 
 
MDA-MB231 cells cultured with RPMI/H medium were assessed for migration by 
comparison to migrated cells cultured in control medium, (figures 4.12) where proliferation 
was inhibited by hydroxyurea.  
  
 
 
Figure 4.12. The migration Assay before and 
after incubation of scraped MDA-MB231 cells in 
the respective media. A) Scraping of MDA-
MB231 for the migration assay using a line drawn 
underneath the culture dish to simplify scraping. 
B) MDA-MB231 cells after 24 h of incubation in 
RPMI, RPMI/JAHA, RPMI/H, RPMI/H/JAHA. 
The results shown were performed in triplicates. 
Bar=200 μM. 
 
 
 
 
 
 
Chapter 4: Results 
 
80 
 
For the evaluation of the wound assay, the migrating MDA-MB231 cells were counted and 
statistical analysis was applied using the Microsoft Office Programme Excel 2007. Since the 
migration assay was performed in triplicates, a mean value of all counted areas, five in total, 
for each of the three plates was taken (tables 4.1-4.4). In addition, the standard deviation was 
calculated for every culture dish. The probability (p) value was calculated for comparison of 
the RPMI and the RPMI supplemented with JAHA to evaluate the statistical significance 
observed amongst the migrating MDA-MB231 cells stimulated by the respective media. For 
the final evaluation, the averaged mean value with the respective standard deviation was 
plotted in a graph (figure 4.13).  
 
   
 
Figure 4.13. Evaluation of the migration assay. The histogram shows the total number of migrated MDA-
MB231 cells cultured in RPMI medium supplemented with JAHA compared to cells grown in plain medium. 
(control). Proliferation effects were excluded by the addition of 2 mM hydroxyurea. The result was evaluated 
from triplicate assays. ** indicates p<0.01. 
 
 
In this case we observed that JAHA had no effect on the motile behaviour of MDA-MB231 
cells but influence only the proliferation of this cell line, the data are shown in the tables 
below. These data were obtained in collaboration with Prof. Tobiasch of the University of 
Applied Sciences of Bonn-Rhein-Sieg, in Germany. 
 
 
 
 
 
 
** 
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Table 4.1. Statistical data of a migration assay performed with MDA-MB231 cells stimulated with control 
RPMI medium. This experiment was performed in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2. Statistical data of a migration assay performed with MDA-MB231 cells stimulated with control 
RPMI medium supplemented with 8.45 μM of JAHA. This assay was performed in triplicate. 
 
 
 
 
 
 
 
 
 
Table 4.3. Statistical data of a migration assay performed with MDA-MB231 cells stimulated with control 
RPMI medium supplemented with 8.45 μM of JAHA and with 2 mM of H-hydroxy urea. This assay was 
performed in triplicate. 
 
 
 
Table 4.4. Statistical data of a migration assay performed with MDA-MB231 cells stimulated with control 
RPMI medium supplemented with 2 mM of H-hydroxy urea. This assay was performed in triplicate. 
  
RPMI        
Number of count 
area 1 2 3 4 5 
Mean 
value 
Standard 
deviation 
Plate 1 1216 1043 1149 1237 1231 1175,2 81,79364278 
Plate 2 1048 1220 1065 1000 1100 1086,6 82,8118349 
Plate 3 1500 1024 1030 1012 1031 1119,4 212,8962188 
Total           1127,066667 75,39989955 
RPMI+JAHA        
Number of count 
area 1 2 3 4 5 
Mean 
value 
Standard 
deviation 
Plate 1 478 571 590 585 579 560,6 46,71509392 
Plate 2 473 475 500 353 377 435,6 65,86956809 
Plate 3 589 602 534 570 596 578,2 27,48090246 
Total           524,8 19,19434661 
RPMI+H+JAHA        
Number of count 
area 1 2 3 4 5 
Mean 
value 
Standard 
deviation 
Plate 1 519 397 394 470 615 479 92,36611933 
Plate 2 392 369 392 414 400 393,4 16,33401359 
Plate 3 543 665 680 637 615 628 53,73081053 
Total           500,1333333 38,01773404 
RPMI+H        
Number of count 
area 1 2 3 4 5 
Mean 
value 
Standard 
deviation 
Plate 1 637 474 645 700 412 573,6 123,6216001 
Plate 2 578 526 608 499 505 543,2 47,74620404 
Plate 3 670 725 637 620 663 663 40,0562105 
Total           593,2666667 46,18691382 
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4.8 Effect of JAHA on ERK and AKT signaling pathways  
 
Activation of ERK is known to regulate cell proliferation (McCubrey et al., 2007). Therefore, 
we investigated whether JAHA reduced cell viability by altering cell survival pathway. We 
assessed the expression of total and phosphorylated ERK1/2 proteins. In MDA-MB231 breast 
cancer cells treated with 8.45 µM of JAHA decreases the phosphorylation of ERK1/2 at Thr 
202 and Ty 204 at 18, 30 h of the treatment and increases the total ERK1/2 level at 48 h as 
shown in figures 4.14-4.15. 
 
 
Figure 4.14. JAHA blocks the activation of p-ERK1/2 at early times. Different total cell lysates were prepared 
and  Western Blot analysis was performed for ERK1/2 and p-ERK1/2 signaling proteins in control and 8.45 µM 
JAHA-treated cells cultured for 18, 30 and 48 h. Beta-actin was used as loading control. 
 
 
  
 
Figure 4.15 JAHA effect on A) ERK1/2 and B) p-ERK1/2 levels in MDA-MB231 cells incubated either in the 
absence (control) or in the presence of 8.45 µM JAHA for 18, 30 and 48 h. The data of the densitometric 
analysis are expressed as mean ± s.e.m. of triplicate experiments. * indicates p<0.05 for JAHA treatment 
compared to control. 
 
 
 
   A)   B) 
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We also assessed the effects of JAHA on cell survival signaling pathway regulated by Akt. A 
reduced of total Akt in 8.45 µM JAHA-treated MDA-MB231 cells after 30 hours was 
observed while no significant change in the AKT phosphorylated expression at Ser 473 was 
noticed in figures 4.16-4.17. (These data were obtained in collaboration with Prof. Maria 
Carmela Roccheri, Dr. Roberto Chiarelli and Dr. Liana Bosco of Department STEBICEF of 
the University of Palermo). 
 
 
 
Figure 4.16. Different total cell lysates were prepared and Western Blot analysis was performed for AKT and p-
AKT signaling proteins in control and 8.45 µM JAHA-treated cells cultured with for 18, 30 and 48 h. Beta-actin 
was used as loading control. 
 
 
 
           
 
Figure 4.17. JAHA effect on A) AKT and B) p-AKT levels in MDA-MB231 cells incubated either in the 
absence (control) or in the presence of 8.45 µM JAHA for 18, 30 and 48 h. The data of the densitometric 
analysis are expressed as mean ± s.e.m. of triplicate experiments. The densitometry analysis was performed by 
Quantity One software. 
 
 
 
 
 
   A)   B) 
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4.9 JAHA influence on DNMT1 protein expression in MDA-
MB231 cells 
 
 
 
 
 
 
 
 
The observed inhibition of DNMT1 activity by JAHA may be due to a reduction of its 
expression. We investigated this effect in MDA-MB232 cells treated with 8.45 µM of JAHA 
compared to control at 18, 30, 48 hours by Western blot analysis, (figure 4.18). JAHA down-
regulated DNA (cytosine-5-)-methyltransferase 1 (DNMT1) after 18 h and until 48 h of the 
treatment. 
 
 
   
 
 
 
 
 
Figure 4.18. A) Different total cell lysates were prepared from JAHA-treated (8.45 µM) and untreated 
proliferating MDA-MB231 cells cultured for 18, 30, 48 h and submitted to Western blot analysis of DNMT1 
protein. Beta-actin was used as loading control. 
B) Densitometric analysis of DNMT1 expression by Quantity One software The data are expressed as mean ± 
s.e.m. of triplicate experiments. * indicates p<0.05 for JAHA treatment compared to control. 
 
 
 
 
 
 
A) 
   B) 
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4.10 Epigenetic effects of JAHA on genomic methylation status in 
MDA-MB231 cells 
 
Histone deacetylase inhibitors (HDACIs) have been actively explored as a new generation of 
chemotherapeutics for cancers, generally known as epigenetic therapeutics. Recent findings 
indicate that several types of HDACIs repress angiogenesis, a process essential for tumor 
metabolism and progression. Changes in genome methylation may be one of the mechanism 
throught which HDACi act as gene expression regulators. The effect of JAHA on DNA 
methylation patterns in the breast cancer cell line was therefore investigated. In particular, 
DNA isolated from MDA-MB231 cells grown for 18, 30 and 48 h, either in the absence or in 
the presence of 8.45 µM JAHA was analysed by MeSAP-PCR, to investigate changes induced 
by the HDACi on global methylation status of genomic DNA. In accordance with this 
method, genomic DNA samples are digested with methylation-insensitive restriction enzyme 
(SDD) followed by methylation-sensitive restriction enzymes (DDD). Comparison of the 
products from PCR amplification using a no-specific primer allows screening for DDD from 
either control or JAHA-treated MDA-MB231 cells and the results are reported in figure 4.19. 
The examination of the PCR fragments differences revealed that treatment with 8.45 µM 
JAHA was effective in modifying the global DNA methylation pattern, as shown by the 
different number, intensity and size of the bands in the matched samples compared with 
untreated MDA-MB231 cells after 48 h. It is worth mentioning that MeSAP-PCR gives no 
indication of the genomic region affected by methylation/demethylation by an external agent. 
 
 
 
    A) 
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Figure 4.19. Methylation-sensitive arbitrarily-primed fingerprintings (right) and relevant densitometry profiles 
(left) of the matched SDD and DDD pairs from either untreated or JAHA-treated MDA-MB231 cells cultured 
for A) 18 h, B) 30 h, C) 48 h. PCR was performed using an arbitrary primer after 16h-restriction enzyme 
digestion with 5X excess of AfaI (single-digested DNA, SDD) or AfaI + HpaII (double-digested DNA, DDD). 
Matching SDD and DDD fingerprinting, differences in appeared/disappeared or increased/decreased bands 
(indicated by arrows) were counted as semiquatitative evidences of different genomewide methylation status. 
The images are representative of three independent experiments and were obtained by SigmaGel Software 
support. 
 
The difference in the DNA methylation pattern between single-digested DNA (SDD) and 
double-digested DNA (DDD) shows us that the second enzyme was able to cut a major 
number of unmethylated CpG-contained sites; then, it is possible to deduce that to the 
increasing of the variation of genomic methylation pattern, corresponds a decreasing of the 
genomewide DNA-methylation status in an inversely-proportional manner.  
 C) 
 B) 
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Finally, the data here reported show an evident hypomethylation of the DNA after 48 h of 
treatment with JAHA (figure 4.20). These data were obtained in collaboration with Prof. 
Fabio Caradonna of Department STEBICEF of the University of Palermo. 
 
            
Figure 4.20. Variation of the genomic methylation pattern in control and JAHA-treated cells. In the ordinate the 
pattern refers to the total number of different bands between the treated and control samples at different times. 
The assay was performed in triplicate. 
 
4.11 Differentially-Expressed Genes in MDA-MB231 cell treated 
with JAHA 
 
To search for differentially-expressed genes in MDA-MB231 cells treated at 18, 24, 48 h with 
JAHA 8.45 µM, DD-PCR was performed on enriched mRNA samples isolated from control 
and treated cell preparations, in the presence of primer combinations as listed previously in 
Materials and Methods section. After polyacrylamide gel electrophoresis and silver stain, 
several bands appeared differently expressed in either control and treated sample, and they 
were cut from the gel (figure 4.21).  
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Figure 4.21. 6% polyacrylamide gel of cDNA preparations from MDA-MB231 cells cultured with (T) and 
without (C) JAHA at different time (18, 24, 48 h). AB, BC, DE, FG, and HI indicate the different primer pairs as 
listed previously. M=100 bp DNA marker (Invitrogen) for 48 h gels and M=50 bp DNA marker (Invitrogen) for 
24 and 18 h gels. The arrows indicate the differentially-displayed bands that have been identified by silver stain. 
 
The eight bands, indicated in the figure with arrows were submitted to further analysis. To 
this purpose, the cDNA contained in the bands was purified, re-amplified until purity and 
adequate yield, and then the material was submitted to sequencing. The analysis by FASTA 
showed homology for band 2 with a portion of cDNA of Brefeldine A-Inhibited guanine 
nucleotide-exchange protein 3 (acc. nr. NM_020340.3), Protein kinase C epsilon (acc. nr. 
NM_005400.2), Mediator of RNA Polymerase II trascription subunit 25 (acc. nr. 
NM_030973.3) and ER-Golgi intermediated compartiment 2 KDa protein (acc. nr. 
NM_016570.2); for band 4 with a portion of cDNA of Protein kinase C iota (acc. nr. 
NM_002740.5), for band 5 with a portion of cDNA of Inactive_N-acetylated-alpha-linked 
acidic peptidasi-like protein 2 (acc. nr. NM_207015.2) and neurotrophic tyrosine kinase, 
receptor, type 2 (acc. nr. NM_001018064.1) for band 7 with a portion of cDNA of DNA 
repair protein (acc. nr. NM_005732.3), and for band 8 with a portion of Leucina-Rich-Repeat 
and calponin homology domain containing protein 1 (acc. nr. NM_001164211.1). No 
sequence identified for 1, 3, 6 bands (table 4.5). 
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Gel bands 
 
 
Gene name 
 
 
Gene reference 
      1  
(cDNA 48h) 
 
No seq. 
 
 
        
 
 
                                                        2 
(cDNA 48h) 
 
Brefeldine A-Inhibited guanine nucleotide-exchange protein 3 
 
PKCε (Protein kinase C epsilon) 
 
MED25 (Mediator of RNA Polymerase II trascription subunit 25) 
 
Ergic2 (ER-Golgi intermediated compartiment 2KDa protein) 
 
NM_020340.3 
    
    NM_005400.2 
 
NM_030973.3 
    
    NM_016570.2 
 
 
                                                                3 
(cDNA 48h) 
 
                                                    No seq. 
 
 
 
 
                                                         4  
(cDNA 48h) 
 
 
PKCι  (Protein kinase C iota) 
 
 
NM_002740.5 
 
5 
(cDNA 24h) 
 
NAALAD2 (Inactive_N-acetylated-alpha-linked acidic peptidasi-
like protein 2) 
 
NTRK2 (neurotrophic tyrosine kinase, receptor, type 2) 
 
 
NM_207015.2 
 
NM_001018064.1 
 
 
                                                                      6 
(cDNA 24h) 
 
 
 
 
 
 
 
No seq. 
 
 
 
 
                                                               7 
(cDNA 24h) 
 
Rad50 (DNA repair protein) 
 
NM_005732.3 
 
 
 
 
                                                             8 
(cDNA 18h) 
 
 
Lrch1(Leucina-Rich-Repeat and calponin homology domain 
containing protein 1) 
 
NM_001164211.1 
 
 
 
 
 
Table 4.5  FASTA analysis of cDNAs that showed homology with the sequences obtained for the different 
bands extracted from DD gel. 
 
NCBI has a tool for aligning two sequences provided by the user. The tool is called BLAST 2 
Sequences, which uses the chosen BLAST algorithm to align sequences as if they were found 
in a database search. This can be helpful for observing differences between two sequences, 
however, it still performs local alignments, not global alignments (data showed in the table 
4.6). 
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Table 4.6. Alignment statistics for match. High E values make sense because short sequences were analyzed. 
 
 
Since DD-PCR may give false positive data, experiments were carried out to confirm the data 
obtained. To this purpose, first semiquantitative PCR assays were performed on cDNA 
preparations obtained from control and JAHA-treated MDA-MB231 cells in the presence of 
primers specific for LRCH1, RAD 50, ERGIC 2, Inactive N-acetilated alpha-linked acid 
dipeptidase like-2, Protein kinase iota, NTRK2, Brefeldine A-Inhibited guanine nucleotide-
exchange protein 3, Protein kinase epsilon and MED 25, designed using Primer 3 online 
software (http://primer3.wi.mit.edu). In order to put in evidence the possible presence/absence 
of amplification bands between control and treated samples, thereby confirming the DD-PCR 
data, the cDNAs were submitted to a lower number (i.e 25-35 cycles) of amplification. 
GAPDH was used as a control. The amplified DNA was loaded directly into an agarose gel 
after the PCR process. As shown in figure 4.22, data from this first approach indicated that 
JAHA at 8.45 µM concentration induced the expression of NTRK2 and RAD 50 genes in 
MDA-MB231 breast cancer cells after 48 and 24 h of treatment, respectively, whereas 
expression of Protein Kinase ε was restrained after 48 h of treatment. 
 
Gene name Score E-value Identity Gaps 
ERGIC 37.4 bits (40) 4.5 23/25 (92%) 0% 
PKCε 35.6 bits (38) 9.9 19/19 (100%) 0% 
Brefeldin-A 37.4 bits (40) 4.5 28/30 (92%) 0% 
PKCι 30.2 bits (15) 114 21/21 (100%) 0% 
MED25 35.6 bits (38) 5.4 25/25 (100%) 0% 
RAD50 39.2 bits (42) 0.87 23/24 (96%) 0% 
NAALAD2 37.4 bits (40) 4.9 25/28 (89%) 0% 
NTRK2 37.4 bits (40) 4.9 25/28 (89%) 0% 
LRCH1 37.4 bits (40) 4.9 22/23 (96%) 0% 
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18h            24h           48h
LRCH1
RAD 50 
ERGIC 2 
NAALAD2
Protein kinase ι
NTRK2
Brefeldine
Protein kinase ε
MED 25 
C         T                                                 C       T
35 cycles 25 cycles
LRCH1
RAD 50 
ERGIC 2 
Brefeldine
Protein kinase ε
MED 25 
C
T 
GAPDH
20 cycles
Protein kinase ι
NAALAD2
 
 
Figure 4.22. JAHA influence gene expression in human breast cancer cells. Total RNA isolated from MDA-
MB231 cells treated with DMSO (C), or JAHA (T) at 8.45 µM for 18, 24 and 48 h, was reverse transcribed and 
subjected to 35 and 25 cycles of PCR amplifications with primers specific for: LRCH1 (cDNA 18h), RAD 50 
(cDNA 24h), ERGIC 2 (cDNA 48h), N-acetilated alpha-linked acid dipeptidase like-2 (cDNA 24h), Protein 
kinase iota (cDNA 48h), NTRK2 (cDNA 24h), Brefeldine A-Inhibited guanine nucleotide-exchange protein 3 
(cDNA 48h), Protein kinase epsilon (cDNA 48h), MED 25 (cDNA 48h). PCR of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was included and served as a loading control. The panel shows the amplified PCR 
products (220 bp for LRCH1, 215 bp for RAD50, 196 bp for ERGIC, 229 for NAALAD2, 169 bp for PKCι, 181 
bp for NTRK2, 231 bp for Brefeldine A, 249 bp for PKCε, 188 for MED25 and 414 bp for GAPDH). The arrows 
indicate the differentially expressed genes, i.e. NTRK2 and RAD50 (prominently up-regulated by JAHA) and 
Protein Kinase ε (prominently down-regulated by JAHA). 
 
 
Second, Real Time PCR assays were carried out in order to extend the validation, if appliable, 
of the DD-PCR results. Only the expression of Brefeldine A, Protein kinase epsilon, Protein 
kinase iota, ERGIC 2, MED 25 and RAD50 in control and treated samples was examined. 
This technique utilizes the fluorophore, Sybr Green, which intercalates in a nonspecific 
manner into the DNA double helix, that is formed during the PCR. Sybr Green when excited 
emits a green light whose intensity is proportional to the concentration of amplified DNA. In 
particular the number of the PCR cycle when Sybr Green starts to emit fluorescence is 
proportional to the original amount of cDNA in each sample. As shown in figure 4.23, JAHA 
at 8.45 µM concentration induced the expression of RAD 50 genes after 24 h of the treatment 
in MDA-MB231 breast cancer cells, while reduced the expression of Protein Kinase ε after 
48 h of treatment. No difference was observed for the other genes studied. 
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Figure 4.23. Gene expression (arbitrarily units) levels in MDA-MB231 cells, control and treated with 8.45 µM 
JAHA, assayed through Real time PCR with β-actin used as an internal control. Values are the mean ± s.e.m. of 
two quadruplicate experiments. * indicates p<0.05, ** indicates p<0.01 for JAHA treatment compared to 
control. 
 
The same approach was applied to cells treated with SAHA at the same dosage (8.45 µM) and 
at the same time of exposure (24 h for RAD50 and at 48 h for the other genes). This was 
aimed to check differences and/or similarities in the gene signatures associated to the 
exposure of cells to the two closely-related HDACis. The data obtained show a clear 
reduction in the expression levels of genes PKε, Brefeldine A, PKι and Ergic 2 while no 
significant change in the expression levels of Med 25 and Rad 50 (figure 4.24). 
 
 
Figure 4.24. Gene expression (arbitrarily units) levels in MDA-MB231 cell, control and treated with 8.45 µM 
SAHA, assayed through Real time PCR with β-actin used as an internal control. Values are the mean ± s.e.m. of 
two quadruplicate experiments. * indicates p<0.05, ** indicates p<0.01 for JAHA treatment compared to 
control. 
 ** 
     ** 
**  ** 
 ** 
* 
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Literature data (Huang et al., 2000) have previously reported that SAHA treatment to MDA-
MB231 cells was able up-regulate a number of genes associated with differentiation and/or 
growth inhibition. These genes encode for gelsolin, isopentenyl-diphosphate delta isomerise 
(IDI1), and 1,25-dihydroxyvitamin D-3 up-regulated protein 1 (VDUP1). Induction of these 
genes may contribute to SAHA-mediated pro-differentiating and antiproliferative effects. In 
order to extend the comparative evaluation of the molecular effects of SAHA and JAHA 
moleculaes on MDA-MB231 cells, we checked the effects of JAHA on the expression levels 
of the same genes identified as up-regulated in SAHA-treated cells.  
The results obtained show a similarity of action of SAHA and JAHA on the expression levels 
of the gene examined (figure 4.25). 
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Figure 4.25. Gene expression (arbitrarily units) levels in MDA-MB231 cells, control and treated for 48 h with 
8.45 µM JAHA, assayed through Real time PCR with β-actin used as an internal control. Values are the mean ± 
s.e.m of two quadruplicate experiments.* indicates p<0.05, ** indicates p<0.01 for JAHA treatment compared to 
control. 
 
4.12 Differentially-Expressed Proteins in MDA-MB231 cell treated 
with HDACis 
 
 
 
 
 
 
 
In order to expand the search of JAHA-associated signatures to the protein level, proteomic 
analysis were performed and showed a differential expression of eleven proteins (six, one and 
four associated to 18, 24 and 48 h of treatment with JAHA at 8.45 µM, respectively). Of the 
six proteins associated to 18 h-treatment, four were down-regulated (i.e. AHNAK protein, 
high mobility group protein B2, Cystatin-B, High mobility group protein B1) and two were 
up-regulated (i.e. Ribosome-binding protein 1, Glutaredoxin-1) in treated samples compared 
to controls. A single up-regulated protein (i.e. Hematological and neurological Expressed 1 
  ** 
 * 
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protein) was found in cells treated with JAHA for 24 hours, and four up-regulated proteins in 
cells treated with JAHA for 48 hours (i.e. prelamin-A/C, Ribosome-binding protein, 
Sulfiredoxin-1, Histone H1) (tables 4.7-4.9). 
 
 
 
 
 
 
Table 4.7. Proteomic analysis of proteins differentially expressed in MDA-MB231 cells cultured in control 
conditions and treated with JAHA at 8.45 µM concentration for 18 h. 
 
 
 
 
 
 
 
 
 
Table 4.8. Proteomic analysis of proteins differentially expressed in MDA-MB231 cells cultured in control 
conditions and treated with JAHA at 8.45 µM concentration for 24 h. 
 
 
 
 
 
 
 
 
Table 4.9. Proteomic analysis of proteins differentially expressed in MDA-MB231 cells cultured in control 
conditions and treated with JAHA at 8.45 µM concentration for 48 h. 
 
 
Twenty-two proteins appeared to be differentially expressed in cells treated with SAHA at the 
same concentration of JAHA (sixteen, five and one respectively associated to 18, 24 and 48 h- 
treatment). Of the sixteen proteins identified at 18 h-treatment, six were down-regulated (i.e. 
Reticulocalbin-1, Microtubule-associated protein 1B, Caprin-1, spectrin alpha chain non-
erythrocytic 1 Integrin beta-1, Myristoylated alanine-rich C-kinase substrate) whereas the 
other ones were up-regulated in the treated samples (i.e. Histone H1.0, neuroblast 
differentiation-associated protein AHNAK, Hematological and neurological Expressed 
protein 1, Reticulocalbin-1, Nucleolar and coiled-body phosphoprotein 1, nucleolin, 
cod. Protein qvalue ratio fold change peptides 
Q09666 Neuroblast differentiation-associated protein AHNAK 0.00079 1.35 1.35 276 
P26583 High mobility group protein B2 0.00158 2.44 2.44 12 
P04080 Cystatin-B 0.02422 2.94 2.94 7 
Q9P2E9 Ribosome-binding protein 1 0.02587 0.61 1.64 22 
P09429 High mobility group protein B1 0.08112 2.70 2.70 11 
P35754 Glutaredoxin-1 0.08978 0.48 2.09 5 
cod. Protein qvalue ratio fold change peptides 
Q9UK76 Hematological and neurological expressed 1 protein 0.02226 0.44 2.26 10 
cod. protein Qvalue ratio fold change peptides 
P02545 Prelamin-A/C 0.00075 0.5 2.00 36 
Q9P2E9 Ribosome-binding protein 1 0.01057 0.42 2.36 24 
Q9BYN0 Sulfiredoxin-1 0.04155 0.12 8.55 3 
P07305 Histone H1 0.04578 0.20 5.05 6 
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Eukaryotic translation initiation factor 4H, 78 kDa glucose-regulated protein, Histidine triad 
nucleotide-binding protein 2 mitochondrial Na(+)/H(+) exchange regulatory cofactor NHE-
RF1, non-erythrocytic spectrin alpha chain 1 Integrin beta-1, Heterogeneous nuclear 
ribonucleoproteins A2/B1). Of the five proteins associated to 24 h-treatment, two were down-
regulated (i.e. neuroblast differentiation-associated protein AHNAK, Nicotinamide 
phosphoribosyltransferase) and three were up-regulated (i.e. Na(+)/H(+) exchange regulatory 
cofactor NHE-RF1, Histone H1, 78 kDa glucose-regulated protein). Finally, a single protein 
was identified down-regulated (neuroblast differentiation-associated protein AHNAK) in the 
samples treated for 48 h (figure 4.10-4.12). 
 
 
 
 
 
 
 
 
 
 
Table 4.10. Proteomic analysis of proteins differentially expressed in MDA-MB231 cells cultured in control 
conditions and treated with SAHA at 8.45 µM concentration for 18 h. 
 
 
 
 
 
 
 
 
 
Table 4.11. Proteomic analysis of proteins differentially expressed in MDA-MB231 cells cultured in control 
conditions and treated with SAHA at 8.45 µM concentration for 24 h. 
 
cod. Protein qvalue ratio fold 
change 
peptides 
P07305 Histone H1.0 0.00035 0.11 9.03 6 
Q09666 Neuroblast differentiation-associated protein  0.00035 1.41 1.41 257 
Q9UK76 Hematological and neurological expressed 1 protein 0.00280 0.47 2.13 10 
Q15293 Reticulocalbin-1 0.00469 2.60 2.60 13 
Q14978 Nucleolar and coiled-body phosphoprotein 1 0.00489 0.54 1.85 17 
P19338 Nucleolin 0.00545 0.51 1.96 28 
Q15056 Eukaryotic translation initiation factor 4H 0.00559 0.49 2.04 7 
P46821 Microtubule-associated protein 1B 0.01389 2.03 2.03 14 
Q14444 Caprin-1 0.01565 1.75 1.75 11 
P11021 78 kDa glucose-regulated protein 0.01623 0.64 1.56 35 
Q9BX68 Histidine triad nucleotide-binding protein 2, 
mitochondrial 
0.01679 0.20 4.97 3 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 0.01776 0.37 2.71 4 
Q13813 Spectrin alpha chain, non-erythrocytic 1 0.01849 1.51 1.51 36 
P05556 Integrin beta-1 0.01877 1.67 1.67 10 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 0.02038 0.55 1.81 14 
P29966 Myristoylated alanine-rich C-kinase substrate 0.05348 1.98 1.98 10 
cod. Protein qvalue ratio fold 
change 
peptides 
Q09666 Neuroblast differentiation-associated protein  0.00072 1.53 1.53 267 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 0.00502 0.26 3.79 4 
P07305 Histone H1.0 0.01815 0.54 1.85 6 
P11021 78 kDa glucose-regulated protein 0.03586 0.55 1.83 35 
P43490 Nicotinamide phosphoribosyltransferase 0.05941 3.04 3.04 9 
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Table 4.12. Proteomic analysis of proteins differentially expressed in MDA-MB231 cells cultured in control 
conditions and treated with SAHA at 8.45 µM concentration for 48 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cod. Protein     qvalue ratio fold 
change 
peptides 
Q09666 Neuroblast differentiation-associated protein  0.08576 2.26 2.26 254 
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5. Discussion 
 
Breast tumour is a widely-spread neoplastic histotype accounting for about 20% of all cancers 
in women; about 15% of breast cancers are triple-negative and the lack of receptors for 
estrogens, progesterone and epidermal growth factor makes neoplastic cells highly aggressive 
and endowed with a higher malignant potential than other breast tumour subtypes (Gluz, et 
al., 2009). Since the pharmacological options for treating triple-negative tumours are limited, 
there has been great interest in testing novel drugs or analogues of pre-existing drugs 
counteracting triple-negative cell growth, which, on the other hand, necessitate of a 
comprehensive biological characterization. SAHA is an archetypal HDACi whose effect on 
triple-negative MDA-MB231 breast cancer cells, the model system used in the present study, 
has been previously tested. In fact, Huang et al., (2000) and Xu et al., (2005) demonstrated 
that SAHA affected cell cycle progression and induced polyploidy, the onset of apoptosis and 
also the up-regulation of several proliferation inhibiting- and differentiation promoting-genes, 
as assessed through DD-PCR assays. The role of SAHA in triggering ROS production and 
dissipating MMP was reported in other cell model systems, e.g. leukemia and colon 
carcinoma cells, although such events have been always associated to the promotion of 
apoptosis or autophagy by the HDACi (Dai et al., 2005; Portanova et al., 2008; Li et al., 
2010). In addition, SAHA was proven to enhance autophagy also in other neoplastic 
cytotypes, such as hepatocellular carcinoma, chondrosarcoma and glioblastoma cells. 
(Yamamoto et al., 1998; Gammoh et al., 2005; Liu et al., 2010).   
In the present study, we have tested the cytotoxic effect on triple-negative MDA-MB231 cells 
of two ferrocene-containing SAHA analogues, JAHA and homo-JAHA, already validated for 
their in vitro extensive inhibitory activity on class I HDACs, although to a lesser degree for 
HDAC8, and class IIb HDAC6 (Spencer et al., 2011). The MTT viability assay demonstrated 
that if exposure to MDA-MB231 cells was prolonged to 72 h, JAHA exhibited an IC50 of 8.45 
µM whereas homo-JAHA, which differs from JAHA for the presence of an additional 
methylene spacer, induced a maximum lowering of cell number down to about 63% only. 
Shorter term treatments of cells with JAHA, i.e. 24 and 48h, determined cell number 
reduction down to about only 84 and 66%, respectively (data not shown). The individuation 
of a cytotoxic effect exerted by JAHA on triple-negative cancer cells prompted a more 
detailed analysis of its mechanism of action, in particular focusing on cell cycle perturbation, 
and the possible onset of apoptosis and/or autophagy, coupled to ROS over-production and/or 
MMP dissipation.  
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Flow cytometric analysis of cell cycle phases produced similar data to those obtained on 
MCF-7 cells, (Spencer et al., 2011) which are shared with other HDACi (e.g. SAHA, 
trichostatin, apicidin, psammaplin A), i.e. a perturbation of S phase entry and a delay at G2/M 
transition, (Ueda et al., 2007; Ahn et al., 2008; Yamamoto et al., 2008; Noh et al., 2009; 
Knutson et al., 2012) although in our model system we did not observe apoptotic cell death as 
with the other HDACi cited, this being a distinctive feature of JAHA.
 
The most intriguing 
results on JAHA mechanism of action regard its ability to induce early ROS production and 
subsequent MMP dissipation and autophagy inhibition, and the reversion of the cytotoxic 
effect obtained by co-treatment with either anti-oxidant or autophagy-promoter compound. 
It is well-known that ROS are generated by mitochondria where a multiplicity of producing 
sources exist and where also ROS detoxifying systems are actively operating; therefore, the 
net intracellular amount of ROS derives from the imbalance of ROS production, removal and 
extra-mitochondrial release (Andreyev et al., 2005). It can be hypothesized that JAHA 
treatment induces an oxidative stress due to mitochondrial defence failure, such as structural 
impairment and/or loss of matrix solutes (e.g. glutathione) through the permeability transition 
pores. On the other hand, initial ROS production may induce the onset of a “vicious cycle” 
(Andreyev et al., 2005) i.e. a further exacerbation of ROS formation due to the activation of 
additional ROS-generating sites within the mitochondria, which might be directly responsible 
of the following MMP collapse as already reported in other cell model systems
 
(Abramov et 
al., 2007; Rogalska et al., 2008) and may be restrained in the presence of the anti-oxidant 
BHT.  
Autophagy, i.e. the formation of double membrane-autophagosomes sequestering cytoplasmic 
material which is digested due to subsequent fusion of the vesicles with the lysosomes, plays 
a complex role in breast cancer. In fact, some authors consider autophagy as a tumour 
suppressor mechanism leading to cell death, whereas other literature data strongly support the 
concept that this process is necessary to provide energy  and basic elements allowing tumour 
cells survive under conditions of metabolic stress, due to oxygen and nutrient shortage and 
rapid proliferative rate (Armstrong et al., 2010). A number of published papers suggest that 
autophagy rate in MDA-MB231 cells is constitutively elevated, thereby playing a likely pro-
survival role. For example, it is acknowledged that inhibition of autophagy sensitizes MDA-
MB231 cells to the lethal effects of chemical or physical agents (e.g. sulforaphane and 
capsaicin treatment, or ionizing radiations), and that MDA-MB231 cells are resistant to 
rapamycin effects, probably due to their elevated phospholipase D activity that leads to the 
formation of phosphatidic acid, a lipid involved in autophagosome formation
 
(Chen et al., 
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2003; Chang et al., 2007; Apel et al., 2008; Choi et al., 2010; Kanematsu et al., 210; Moreau 
et al., 2012). The data here presented clearly indicate that JAHA can be included in the list of 
those molecules that trigger autophagy inhibition and deprive cells of such protective 
mechanism, which can be restored upon rapamycin co-incubation, addressing them to death. 
It is known that mitochondria play a central and complex role in autophagy. Recently, 
Okamoto, (2011) reported that MMP plays a role in autophagy regulation, and that defective 
mitochondria may impair the autophagic flux and vice versa through a protein kinase A-
dependent mechanism. In addition, Kathiria et al., (2012) demonstrated that ROS up-
regulation following mitochondrial membrane depolarization led to autophagy inhibition in 
human intestinal epithelial cells, and Karantza-Wadsworth et al., (2007) proposed that in 
cases of defective autophagy breast tumour cells lose the ability to adapt to metabolic stress, 
produce insufficient ATP and accumulate damaged mitochondria with excessive ROS. In 
light of such evidence, we cannot exclude the occurrence of an interplay between the early 
ROS increase, MMP collapse and autophagy down-regulation in JAHA-treated MDA-MB231 
cells, although further studies will be required to confirm this hypothesis. Importantly, Rao et 
al., (2012) reported the superior anti-cancer activity of co-treating triple-negative breast 
cancer cells and xenografts with the pan-HDACi panobinostat and the autophagy inhibitor 
chloroquine; therefore, the possible clinical utilization of the sole JAHA, an HDACi 
possessing an intrinsic autophagy-inhibiting activity, appears to be worth-investigating. 
Noteworthy, the time-course study of JAHA effect on the control of the autophagic flux in 
MDA-MB231 cells revealed a biphasic trend of the biological progress, whose molecular 
basis will deserve further and more detailed investigation.  
HDACis also negatively control angiogenesis, metastasis, and invasion by down-regulating 
the expression of (hypoxia inducible factor) HIF-1α (Fath et al., 2006; Qian et al., 2006), 
matrix metallo-proteinases MMP-2 and MMP-9 (Kim et al., 2004; Liu et al., 2003), 
chemokine (C-X-C motif) receptor 4 (CXCR4) (Qian et al., 2006) endothelial nitric oxide 
synthase (e-NOS) (Rossig et al., 2002) and up-regulating the expression of angiostatic protein 
ADAMTS1 (Chou et al., 2008). To investigate the influence of JAHA on cell migration and 
proliferation, an experimental “scratch assay” was designed in this study, to test the motile 
behaviour of MDA-MB231 breast cancer cells cultured in the presence of 8.45 µM JAHA for 
24 hour. To distinguish whether proliferation or migration was increased, 2 mM hydroxurea 
was used as a control in combination with JAHA to inhibit cell proliferation (Clay et al., 
2001). Our preliminary data indicate that JAHA does not influence cell migration. 
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Recent study demonstrated also that multi-platform classification of breast cancers is based on 
genomic sequencing, gene expression profiling, and proteomics. For this reason in this study 
we wanted to evaluate some molecular aspects of the effects exerted by JAHA on MDA-
MB231 breast cancer cells.  
The results obtained by differential display PCR and confirmed by Real Time-PCR assay 
showed that the NTRK2, BDNF/NT-3 growth factors receptor was upregulated in treated 
cells. BNDF is a nerve growth factor (NGF) like neurotrophin 3 (NT3), and neurotrophin 4/5 
(NT-4/5). These factors are known especially for their roles in the development and 
maintenance of the nervous system, where they stimulate the survival, differentiation and 
neuronal plasticity. Their activity is mediated by tyrosine kinase receptors (TRK) specific for 
each neurotrophin (Knüsel et al., 1994). Currently, these receptors are considered potential 
targets for cancer treatment, in particular for breast cancer cells negative for the estrogen 
receptor, such as TNBC. Literature data show that BDNF and NT4/5 are both expressed and 
secreted by cells in breast cancer and they have been shown to directly contribute to the 
progression of mammary carcinogenesis through an autocrine "loop" of apoptosis inhibition 
that is achieved through TrkB-specific receptors (Yang et al., 2012). It is conceivable that the 
increase of NTRK2 expression level following treatment of cells with JAHA represents a 
defense cellular response against the cytotoxic effect which is, however, unable to re-establish 
the viability of MDA-MB231 cells exposed to the HDACi.  
Our data confirm also the down-regulation of the expression of the gene coding for PKC and 
the up-regulation of that coding for Rad 50 in cells treated with JAHA at 8.45 µM 
concentration. PKCε is a phospholipid-dependent serine/threonine kinase regulated by DAG 
and PS but does not require Ca
2+
 for activation which plays an essential role in the regulation 
of various cellular processes linked to the involvement of cytoskeletal proteins, such as 
adhesion, motility, cell cycle, growth and the regulation of neuronal ion channels. This 
protein is also involved in the immune response, in the invasion of cancer cells and in the 
regulation of apoptosis. During cytokinesis, it forms a complex with YWHAB (Tyrosine 3-
monooxygenase Tryptophan 5-monooxygenase Activation Protein, Beta Polypeptide) 
(http://www.genenames.org), important for the division of the mother cell into two daughter 
cells, and facilitates the abscission with a mechanism that may involve the regulation of RhoA 
factor (Sauter et al., 2008). PKCε is over-expressed in epithelial tumors including those of the 
breast (Pal al., 2013). It is known that the down-regulation of this protein alters the oncogenic 
pathway of NF-kB in breast cancer cells bringing them to apoptotic death (Körner et al., 
2013). Rad 50 protein contains a long internal coiled-coil domain that folds back on itself, 
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bringing the N- and C-termini together to form a globular ABC ATPase head domain. Rad 50 
can dimerize both through its head domain and through a zinc-binding dimerization motif at 
the opposite end of the coiled-coil known as the “zinc-hook” (Hopfner et al., 2002). RAD 50 
forms a complex with MRE11 and NBS1 (also known as Xrs2 in yeast). This MRN complex 
(MRX complex in yeast) binds to broken DNA ends and displays numerous enzymatic 
activities that are required for double-strand break repair by nonhomologous end-joining or 
homologous recombination. Gene knockout studies of the mouse homolog of Rad 50 suggest 
that it is essential for cell growth and viability.  
Subsequently, we wanted to assess whether the effect induced by JAHA in this cell line is 
comparable to that induced by its analogue. The data obtained show that SAHA is able to 
induce a down-regulation of a higher number of analysed genes than JAHA, in particular of 
Ergic 2 (ER-Golgi intermediated compartiment 2KDa protein), protein kinase C iota (PKCι), 
Protein kinase C ε (PKCε) and Brefeldine a-Inhibited guanine nucleotide-exchange protein 3 
except MED25 (mediator of RNA Polymerase II trascription subunit25) which encodes a 
component of the complex transcriptional coactivator defined with the name of mediator 
complex and Rad 50.  
PKCι is a calcium-independent serine/threonine protein kinase  and does not require 
phosphatidylserine, diacylglycerol (DAG) for activation. It plays a protective role against 
apoptotic stimuli, is involved in the activation of NF-kB in cell survival, differentiation and 
polarity, and contributes to the regulation of dynamics of the microtubules in the early 
secretory pathway. An over-expression of PKCι was found in a "subset" of breast cancer. The 
depletion of PKCι in breast cancer cell lines in which the gene is over-expressed increases the 
number of senescent cells. In this case in the absence of a response to DNA damage induced 
by p21 and aurora kinase VX-680 inhibitor, senescence is likely to be triggered by defects in 
the mitosis process. This function, however, seems to be limited to tumor cells (Paget et al., 
2012).  
ERGIC 2, also called PTX1, plays a possible role in the chaperone protein transport between 
the rough endoplasmic reticulum and the Golgi apparatus. The protein contains two 
hydrophobic transmembrane domains that help to anchor the molecule on the ER membrane, 
its large luminal domain is addressed within the ER lumen while the amino and carboxy-
termini are facing the cytosol. ERGIC2, Erv41p homolog in yeast, forms a complex with two 
other proteins, hErv46 (Ergic3 homologous in mammalian) and ERGIC32 (also known as 
ERGIC1), acting as a "shuttle" for protein trafficking between ER and Golgi (Żak et al., 
2012). These ERGIC also seem to interact with several proteins, such as otoferlin, SNARE 
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(syntaxin 5, syntaxin 17, syntaxin 18, rBet1, Sec22) and small GTPases, such as Rab1 and 
Rab2 (Appenzeller-Herzog et al., 2006; Muppirala et al., 2011). Therefore, it can play an 
important role in cellular functions in addition to acting as a shuttle for the trafficking of 
proteins. ERGIC2 is a ubiquitously expressed nuclear protein that appears to be 
downregulated in prostate cancer (Kwok et al., 2001). There is no data in the literature in 
relation to breast cancer, and therefore the result obtained in this work represents the first 
experimental evidence of ERGIC2 as molecular marker activity of the HDACi JAHA in 
TNBC cells.  
Brefeldine A-Inhibited guanine nucleotide-exchange protein 3 is involved in regulating 
vesicular transport in the Golgi apparatus by promoting the activation of ARF1/ARF5/ARF6. 
The only data related to its involvement in mammary tumorigenesis, concern the activation of 
the estrogen/estrogen receptor α pathway in estrogen receptor-positive cells (Kim et al., 
2009).  
It is known that by Differential Display PCR, some authors had identified molecular targets 
associated with differentiation and/or growth inhibition in human breast cancer cells treated 
with SAHA. These genes were IDI1, VDUP1 and gelsolin (Lili et al., 2000).  
IDI1 is an enzyme important for is oprenoid biosynthesis and the prenylation of proteins 
(Hahn et al., 1996). Post-translational modification by prenylation is important for the 
function of certain proteins, such as the ras p21/ras p21-like small GTP-binding proteins. Ras 
proteins have been shown to regulate cell growth, differentiation, and apoptosis (Olson et al., 
2000). For instance, during TPA induced differentiation of hematopoietic leukemia cell lines, 
ras p21 is activated (Katagiri et al., 1994), and ras p21/ras p21-like G proteins are markedly 
induced (Adachi 1992), suggesting potential roles of ras proteins in cell differentiation. 
VDUP1 was first reported as a novel protein up-regulated by 1,25-dihydroxyvitamin D-3 in 
HL60 cells (Chen et al., 1994). Later, the rat VDUP1 homologue was found to be down-
regulated in N-methyl-N-nitrosourea (MNU)-induced rat mammary tumors (Young et al., 
1996), and up-regulated in a cell line derived from MNU-induced rat mammary tumor after 
treatment with 1,25-dihydroxyvitamin D3, which also inhibited cell growth (Yang et al., 
1998). VDUP1 recently was found to be identical to the thioredoxin-binding protein-2 (TBP-
2), which acts as a negative regulator of thioredoxin (TRX) function and expression 
(Nishiyama et al., 1999).  
TRX is a disulfide oxidoreductase, originally discovered as an adult T-cell leukemia-derived 
factor from T-lymphotropic virus type I transformed lymphocytes (Tagaya et al., 1989). TRX 
is overexpressed in some human tumor cells (Fujii et al., 1991; Berggren et al., 1996), and has 
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cell growth stimulating effects (Wakasugi et al., 1990; Gasdaska et al., 1995). Moreover, 
TRX increases colony formation in soft agarose when transfected into human breast cancer 
cells; whereas, a TRX dominant-negative mutant inhibits tumor cell growth (Gallegos et al., 
1996). Thus, it is plausible that down-regulation of TRX expression and function by VDUP1 
might contribute to the pro-differentiating and antiproliferative effects of 1,25-
dihydroxyvitamin D3 observed in promyelocytic leukemia cells and MNU-induced rat 
mammary tumor cells (Chen et al., 1994; Yang et al., 1998), and the antiproliferative and 
potential pro-differentiating effects of SAHA on human breast cancer cells.  
Another differentiation-associated gene, gelsolin, also was induced drastically by SAHA. 
Gelsolin, an actin-regulatory protein, is down-regulated in a variety of cancer cells (Tanaka et 
al., 1995; Mielnicki et al., 1999), and up-regulated in differentiated keratinocytes (Schwartz et 
al., 1994; Olsen et al., 1995) and in cancer cells when induced to differentiate (Dieffenbach et 
al., 1989). Interestingly, as IDI1, gelsolin also is up-regulated in human promyelocytic 
leukemia HL60 cells when induced to differentiate by phorbol myristate acetate 
(Kwiatkowski et al., 1988). As a candidate tumor suppressor, gelsolin, when reintroduced into 
cancer cells, greatly reduces the colony-forming ability and in vivo tumorigenicity of cancer 
cells (Tanaka et al., 1995; Tanaka et al., 1999). In this work we demonstrate that the SAHA-
homologue JAHA is capable to induce the same up-regulation of these genes as reported for 
SAHA by Huang et al., (2000). 
Taken the results from gene expression experiments together, it appears that JAHA, although 
sharing some common features with SAHA has a more restricted effect, at least under the 
experimental conditions tested.  
JAHA does not only influence gene expression but also protein accumulation, as shown by 
proteomic analyses aimed to evaluate the different effect induced by the two HDACis JAHA 
and SAHA on MDA-MB231 cells. Also in this case the first one appears to have a more 
limited and discriminative effect on up and down-regulation of the protein products. 
Following treatment with JAHA we observed an up-regulation of Ribosomal binding protein-
1, the glutaredoxin-1 and sulfiredoxin-1 which can be tentatively interpreted as an attempt of 
cells to counteract the HDACi-induced stress in the intracellular redox homeostasis of the 
endoplasmic reticulum to the accumulation of misfolded proteins (Li et al., 2013; Tsai et al., 
2013). Furthermore, the late accumulation of pre-laminae A/C is symptomatic of an inhibition 
of the post-translational prenylation processes in the endoplasmic reticulum, by analogy with 
published data regarding the effect of the anti-tumor R115777 molecule (Kelland et al., 2001). 
The down-regulation of protein Histone H1.0, Hematological and neurological expressed-1 
Chapter 5: Discussion 
 
104 
 
and AHNAK is a common aspect between JAHA and SAHA, but given the scarcity of data 
on the biological activity of these proteins it is not possible to hypothesize the effect of the 
specific cellular modulation of their expression.  
As already mentioned, the types of proteins differentially accumulated after the treatment with 
SAHA appear to be more numerous and varied, and they primarily include the scaffold 
protein NHE-RF1, which is down-regulated together with Microtubule-Associated protein-
1B, the α chain of non-erythrocyte spectrin and integrin β1, whereas other proteins, such as 
intranuclear Nucleolar and coiled-body phosphoprotein 1 and Eukaryotic translation initiation 
factor 4H,  nucleolin and HnRNP A2/B1, were found to be up-regulated. Probably, such up-
regulation attempts to establish a "drug resistance" (Hu et al., 2011; Han et al., 2014), together 
with the over-expression of Histidine triad nucleotide-binding protein 2, which is an AMP-
lysine hydrolase that acts as a mitochondrial "apoptotic sensitizer" (Martin et al., 2006). 
Regarding the proteins with membrane localization, we observed the increase of the 
accumulation of GRP78, a stress-induced chaperonin of the endoplasmic reticulum (Niforou 
et al., 2014). Regarding the cytoplasmic proteins, after 24 h of treatment we observed the 
down-regulation of the anti-apoptotic protein Myristoylated alanine-rich C kinase substrate, 
and the Nicotinamide phosphoribosyltransferase, which reduces the proportion of intracellular 
NAD+, and is involved in the process of cell death (Tan et al., 2013), whereas the down-
regulation of Caprin-1 may be involved in cell cycle arrest at the G1 phase (Wang et al., 
2005). Finally, SAHA suppressed the expression of reticulocalbin as reported in Tong et al., 
(2008).  
Basal-like tumors are often characterized by frequent mutations in the PI3K-AKT pathway 
and elevated expression of phospho-AKT as reported in Cancer Genome Atlas Network, 
(2012). Akt, plays a critical role in controlling survival and apoptosis (Burgering et al., 1995; 
Franke et al., 1995; Franke et al., 1997). This protein kinase is activated by insulin and 
various growth and survival factors to function in a wortmannin-sensitive pathway involving 
PI3 kinase (Burgering et al., 1995; Franke et al., 1995). Akt is activated by phospholipid 
binding and the activation is due to phosphorylation at Thr308 by PDK1 (Cross et al., 1995) 
and within the carboxy terminus at Ser473. The PI3K/AKT/mTOR pathway plays a key 
regulatory function in cell survival, proliferation, migration, metabolism, angiogenesis, and 
apoptosis. This pathway is constitutively activated in various malignancies, including breast 
cancer (Hernandez-Aya et al., 2011). The PI3K pathway is up-regulated in basal-like 
carcinomas, as shown by a significantly increased activation of downstream targets, AKT and 
mTOR (Marty et al., 2008). López-Knowles et al., (2010) found that PI3K pathway activation 
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was significantly associated with ER/PR negative status, high tumor grade, and a “basal-like” 
phenotype, where 92% of tumors had an altered PI3K/AKT pathway (López-Knowles et al., 
2010). Also Raf/mitogen-activated protein kinase (MAPK) kinase 1/2 (MEK1/2)/extracellular 
signal-regulated kinase 1/2 (ERK1/2) pathway is frequently dysregulated in neoplastic 
transformation (Dent et al., 2005; Valerie et al., 2007). The Ras/Raf/MEK/ERK cascade 
couples signals from cell surface receptors to transcription factors, which regulate gene 
expression. Furthermore, this cascade also regulates the activity of many proteins involved in 
apoptosis. This pathway is often activated in certain tumors by chromosomal translocations 
such as BCR-ABL, mutations in cytokine receptors or over-expression of wild type or 
mutated receptors, e.g. EGFR. The Raf/MEK/ERK pathway also has profound effects on the 
regulation of apoptosis via the post-translational phosphorylation of apoptotic regulatory 
molecules including Bad, Bim, Mcl-1, caspase 9 and, more controversially, Bcl-2. This 
pathway has diverse effects which can regulate cell cycle progression, apoptosis or 
differentiation (Steelmanet al., 2004). ERK1 and ERK2 are 44 and 42-kDa MAPKs, 
respectively, and exhibit a high homology in the protein level. Both these isoforms appear 
inactive in quiescent cells, but upon cell stimulation their activity elevates rapidly. Activation 
of ERKs requires phosphorylation of two regulatory residues, threonine and tyrosine, that 
reside in a TEY phosphorylation motif 1 (Payne et al., 1991; Canagarajah et al., 1997). This 
phosphorylation seems to be mediated solely by its upstream activators MAPK/ERK kinases 
(MEK), (Seger et al., 1992), which phosphorylate both regulatory residues of ERK. However, 
the activity of ERK in stimulated cells is regulated not only by MEK, but also by the action of 
various phosphatases, which remove phosphates from either the Thr alone, Tyr alone, or both 
residues, to render the ERK inactive (Gopalbhai et al., 1998). ERKs appear to be important 
regulatory molecules, which by themselves can phosphorylate regulatory targets in the 
cytosol, phosphorylate substrates in the nucleus or transmit the signal to the MAPKAPK 
level. Treatment with HDACis of multiple tumor types has resulted in potent inhibition of Akt 
and Erk pathways. For this reason, we evaluated the effect of JAHA on the two survival 
proliferative pathways, and the data showed that JAHA is able to indued a significative 
alteration on ERK pathway. 
A recent study suggested that DNA methylation in colon cancer cells and in NIH 3T3 cells 
may be regulated by ERK activity (Lu et al., 2007). To determine if JAHA might be exerting 
effects on DNA methylation through ERK, we first examined the effect of JAHA on ERK 
activity, as assessed by modulation of ERK phosphorylation status. Our results show that 
ERK phosphorylation was completely inhibited by exposure to JAHA, whereas the total 
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levels of ERK protein were affected only in 48 h. By contrast, there were no consistent effects 
by the HDACi on the levels of phospho-AKT. These results raised the possibility that the 
HDACi might be regulating DNA methylation and gene expression through ERK. We 
therefore tested this hypothesis by examining the effect of JAHA treatment on DNMT1 
protein accumulation and demonstrated that the HDACi, which inhibited ERK activity, also 
down-regulated DNMT1. Down-regulation of DNMT1 resulted in demethylation of global 
DNA after about 48 h of exsposure, suggesting that some genes, like those acting as tumor 
suppressor, could be expressed after such epigenetic change and cause cell cycle arrest and 
apoptosis. These data confirm the model supported by Sibaji et al., (2011) in which they 
described how HDACis inhibit ERK activation through a direct inhibitory effect on ERK 
phosphorylation, and that this event modulates negatively DNMT1 protein levels. DNMT1 
down-regulation influences the methylation status of the DNA. Furthermore, in light of the 
evidence that DNA demethylation can regulate diverse cellular processes in normal and 
malignant cells, we can hypothesize that JAHA may influence gene expression also in a 
manner alternative to that of histone acetylation which may have prominent and broad 
implications.  
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6. Conclusion 
                                                              
In conclusion, two different SAHA analogues, JAHA and homo-JAHA, obtained by 
manipulation of SAHA aryl cap and assayed for their inhibitory action on purified HDACs,
 
(Spencer et al., 2011) have been tested for their ability to restrain survival of a TNBC cell line 
in vitro. Of the two compounds, only JAHA exhibited a remarkable activity on MDA-MB231 
cell viability and growth with an IC50 of 8.45 µM at 72 h. This indicates that the additional 
methylene spacer present in homo-JAHA, which in the in tube assay exhibited a similar 
profile to that of JAHA for HDACs except HDAC6 and -8, affects its activity in a cellular 
environment, and underlines the importance of a detailed biological characterization of 
promising bioinorganic probes for HDACis on specific cell model systems.  
Thus, JAHA, a ferrocene-derivative of SAHA, provides a fascinating tool for studying the 
interactions of bioorganometallic agents in breast cancer (Osella et al., 2005; Spencer et al., 
2012). The results from biological and molecular assays of JAHA activity highlight the clear 
involvement of oxidative damage of autophagy inhibition in cytotoxicity expanding the list of 
autophagy-regulating drugs and also giving an additional example of the role played by 
autophagy inhibition in breast cancer cell death; its involvement in the molecular and 
biochemical pathways and the possible epigenetic effect on the DNA methylation status.  
For all this reason the future prospective will be to test this compound in vivo situation 
(animals and human trials) to confirm this date and to hope that JAHA become a promising 
anticancer drug for prevention and/or therapy of “aggressive” breast carcinoma. 
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7. Future work 
 
 
The future work will be focussed on the confirmation of the modality of cell death as analysed 
by flow cytometry. To this purpose, we will perform Western blot analyses to evaluate the 
level of expression of some apoptotic markers as indicators of increased cell death after the 
treatment. Moreover, we will carry on further assays to confirm the DNA methylation state in 
MDA-MB231 cell line, both control and treated with JAHA, by immunostaining of 5-
methylcytosine in metaphasic chromosomes and, at gene level, by Methylation Sensitive 
Restriction Endonuclease-PCR. 
An interesting aspect to be checked, related to the possible genotoxicity of JAHA, is the 
evaluation of chromosomal damage. To this purpose, it will be possible to perform the 
micronuclei test which is simple and quick, but alone is not sufficient to distinguish between 
broken or whole chromosome loss. To determine more precisely the presence of whole 
chromosomes with their centromeres in micronuclei it will be necessary to use the technique 
of FISH hybridization with centromeric DNA as probes (Becker et al., 1990) according to the 
protocol of Antonacci et al., (1995). In addition, the test of sister chromatid exchanges (SCE) 
will be performed to analyze the chromosomal damage induced on cell lines treated with 
JAHA, in parallel with the Comet assay, a sensitive method, qualitative and quantitative, 
useful to detect single and double strand breaks in the DNA molecule, alkali-labile sites and 
incisions caused by the activities of nucleotide excision repair.  
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